[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EP1254113A1 - N-substituted 2-cyanopyroles and -pyrrolines which are inhibitors of the enzyme dpp-iv - Google Patents

N-substituted 2-cyanopyroles and -pyrrolines which are inhibitors of the enzyme dpp-iv

Info

Publication number
EP1254113A1
EP1254113A1 EP01946849A EP01946849A EP1254113A1 EP 1254113 A1 EP1254113 A1 EP 1254113A1 EP 01946849 A EP01946849 A EP 01946849A EP 01946849 A EP01946849 A EP 01946849A EP 1254113 A1 EP1254113 A1 EP 1254113A1
Authority
EP
European Patent Office
Prior art keywords
optionally substituted
independently
alkyl
aryl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01946849A
Other languages
German (de)
French (fr)
Inventor
Anders Kanstrup
Jane Marie Lundbeck
Lise Brown Christiansen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of EP1254113A1 publication Critical patent/EP1254113A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Definitions

  • the present invention relates to new therapeutically active and selective inhibitors of the enzyme DPP-IV, pharmaceutical compositions comprising the compounds and the use of such compounds for and the manufacture of medicaments for treating diseases that are associated with proteins which are subject to inactivation by DPP-IV, such as type II diabetes and obesity.
  • DPP-IV DPP-IV
  • the present invention provides novel 2-substituted unsaturated heterocyclic compounds, wherein a nitrogen atom in the heterocyclic ring is attached via an amide bond or a peptide bond to an amino acid or an amino acid derivative.
  • These compounds are potent and selective inhibitors of DPP-IV, and are effective in treating conditions that may be regulated or normalised via inhibition of DPP-IV.
  • the invention also concerns pharmaceutical compositions comprising the compounds, a method of inhibiting DPP-IV comprising administering to a patient in need of such treatment a therapeutically effective amount thereof, the compounds for use as a pharmaceutical, and their use in a process for the preparation of a medicament for treating a condition which may be regulated or normalised via inhibition of DPP-IV.
  • DPP-IV Dipeptidyl peptidase IV (EC 3.4.14.5; DPP-IV), also known as CD26. DPP-IV cleaves a dipeptide from the N terminus of a polypeptide chain containing a proline or alanine residue in the penultimate position.
  • treatment is defined as the management and care of a patient for the purpose of combating the disease, condition, or disorder and includes the administration of a compound of the present invention to prevent the onset of the symptoms or complications, or alleviating the symptoms or complications, or eliminating the disease, condition, or disorder.
  • beta cell degeneration is intended to mean loss of beta cell function, beta cell dysfunction, and death of beta cells, such as necrosis or apoptosis of beta cells.
  • C3-C10 cycloalkyl refers to a radical of one or more saturated cyclic hydrocarbon having from 3-10 carbon atoms such as but not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, adamantyl and the like.
  • aryl as used herein includes carbocyclic aromatic ring systems. Aryl is also intended to include the partially hydrogenated derivatives of the carbocyclic systems.
  • heteroaryl as used herein includes heterocyclic unsaturated ring systems containing one or more heteroatoms selected from nitrogen, oxygen and sulphur such as furyl, thienyl, pyrrolyl, heteroaryl is also intended to include the partially hydrogenated derivatives of the heterocyclic systems enumerated below.
  • R 3 is H; C 1 -C 1 0 alkyl optionally substituted with one or more R 4 independently; C 2 - C 1 0 alkenyl optionally substituted with one or more R 4 independently; C 2 -C ⁇ 0 -alkynyl optionally substituted with one or more R 4 independently; C3-C10 cycloalkyl optionally substituted with one or more R 4 independently; C5-C 1 0 cycloalkenyl optionally substituted with one or more R 4 independently; aryl optionally substituted with one or more R 5 independently and/or fused to a C3-C 1 0 cycloalkane; or heteroaryl optionally substituted with one or more R 5 independently and/or fused to a C3-C 1 0 cycloalkane; R 2 may be connected to R 3 by a saturated or unsaturated bridge containing 1-3 carbon atoms, nitrogen atoms, oxygen atoms, or sulphur atoms independently, or a valence bond
  • nn RR 66 iiss C 1 -C 1 0 alkyl, benzyl, or aryl optionally substituted with one or more R 5 independently.
  • troglitazone Among the thiazolidinediones, troglitazone, rosiglitazone and ciglitazone are preferred.
  • acarbose is preferred.
  • the pharmaceutical compositions can be sterilized and mixed, if desired, with auxiliary agents, emulsifiers, salt for influencing osmotic pressure, buffers and/or colouring substances and the like, which do not deleteriously react with the active compounds.
  • the route of administration may be any route, which effectively transports the active compound of the invention which inhibits the enzymatic activity of DPP-IV to the appropriate or desired site of action, such as oral, nasal, pulmonary, buccal, subdermal, intradermal, transdermal or parenteral e.g. rectal, depot, subcutaneous, intravenous, intraurethral, intramuscular, intranasal, ophthalmic solution or an ointment, the oral route being preferred.
  • a typical tablet which may be prepared by conventional tabletting techniques may contain:
  • the compounds of the invention are effective over a wide dosage range. For example, in the treatment of adult humans, dosages from about 0.05 to about 1000 mg, preferably from about 0.1 to about 500 mg, per day may be used. A most preferable dosage is about 0.5 mg to about 250 mg per day. In choosing a regimen for patients it may frequently be necessary to begin with a higher dosage and when the condition is under control to reduce the dosage. The exact dosage will depend upon the mode of administration, on the therapy desired, form in which administered, the subject to be treated and the body weight of the subject to be treated, and the preference and experience of the physician or veterinarian in charge. Generally, the compounds of the present invention are dispensed in unit dosage form comprising from about 0.05 to about 1000 mg of active ingredient together with a pharmaceutically acceptable carrier per unit dosage.
  • dosage forms suitable for oral, nasal, pulmonal or transdermal administration comprise from about 0.05 mg to about 1000 mg, preferably from about 0.5 mg to about 250 mg of the compounds admixed with a pharmaceutically acceptable carrier or diluent.
  • the invention also encompasses active metabolites of a compound of the invention.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

The present invention relates to new therapeutically active and selective inhibitors of the enzyme DPP-IV. Novel 2-substituted unsaturated heterocyclic compounds are provided, wherein a nitrogen atom in the heterocyclic ring is attached via an amide bond or a peptide bond to an amino acid or an amino acid derivative. These compounds are potent and selective inhibitors of DPP-IV, and are effective in treating conditions that may be regulated or normalised via inhibition of DPP-IV.

Description

TITLE
-substi uted 2-cyanopyroles and -pyxrol±nes which are inhibitors of the enzyme DPP-IV
FIELD OF INVENTION
The present invention relates to new therapeutically active and selective inhibitors of the enzyme DPP-IV, pharmaceutical compositions comprising the compounds and the use of such compounds for and the manufacture of medicaments for treating diseases that are associated with proteins which are subject to inactivation by DPP-IV, such as type II diabetes and obesity.
BACKGROUND OF THE INVENTION
Dipeptidyl peptidase-IV (DPP-IV), a serine protease belonging to the group of post-proline/alanine cleaving amino-dipeptidases, specifically removes the two N-terminal amino acids from proteins having proline or alanine in position 2.
Although the physiological role of DPP-IV has not been completely established, it is believed to play an important role in neuropeptide metabolism, T-cell activation, gastric ulceration, functional dyspepsia, obesity, appetite regulation, IFG and diabetes.
DPP-IV has been implicated in the control of glucose metabolism because its substrates include the insulinotropic hormones Glucagon like peptide-1 (GLP-1 ) and Gastric inhibitory peptide (GIP). GLP-1 and GIP are active only in their intact forms; removal of their two N-terminal amino acids inactivates them.
In vivo administration of synthetic inhibitors of DPP-IV prevents N-terminal degradation of GLP-1 and GIP, resulting in higher plasma concentrations of these hormones, increased insulin secretion and, therefore, improved glucose tolerance.
Therefore, such inhibitors have been proposed for the treatment of patients with Type II diabetes, a disease characterised by decreased glucose tolerance.
Unfortunately, the post-proline/alanine cleaving amino-dipeptidase are also implicated in the regulation of the immune system and inhibitors of these enzymes reportedly suppress immune responses. Thus, there is a risk that long-term treatment of type II diabetes with inhibitors of these enzymes may, as a side effect, lead to immuno- suppression.
However, with the recent discoveries of other post-proline/alanine cleaving amino- dipeptidases that share the same substrate and inhibitor specificity as DPP-IV, including DPP-IVb, Attractin, X and QPP, it has become clear that such inhibitors may inhibit multiple members of this group of enzymes. The precise physiological role of each of these post-proline/alanine cleaving enzymes is not well defined. Consequently, it is not clear what the physiological effect would be of inhibiting each of them separately, a subset, or all of them at the same time.
Diabetic dyslipidemia is characterized by multiple lipoprotein defects, including moderately high serum levels of cholesterol and triglycerides, small LDL particles, and low levels of HDL cholesterol. The results of recent clinical trials reveal beneficial effects of cholesterol-lowering therapy in diabetic and nondiabetic patients, thus supporting increased emphasis on treatment of diabetic dyslipidemia. This need for intensive treatment of diabetic dyslipidemia was advocated by the National Cholesterol Education Program's Adult Treatment Panel II.
Obesity is a well-known risk factor for the development of many very common diseases such as atherosclerosis, hypertension and diabetes. The incidence of obese people and thereby also these diseases is increasing throughout the entire industrialised world. Except for exercise, diet and food restriction no convincing pharmacological treatment for reducing body weight effectively and acceptably currently exist. However, due to its indirect but important effect as a risk factor in mortal and common diseases it will be important to find treatment for obesity or appetite regulation. Even mild obesity increases the risk for premature death, diabetes, hypertension, atherosclerosis, gallbladder disease and certain types of cancer. In the industrialised western world the prevalence of obesity has increased significantly in the past few decades. Because of the high prevalence of obesity and its health consequences, its prevention and treatment should be a high public health priority.
At present a variety of techniques are available to effect initial weight loss. Unfortunately, initial weight loss is not an optimal therapeutic goal. Rather, the problem is that most obese patients eventually regain their weight. An effective means to establish and/or sustain weight loss is the major challenge in the treatment of obesity today. Thus there remains today a need in the art for compounds that are useful for inhibiting DPP-IV without suppressing the immune system.
Several compounds have been shown to inhibit DPP-IV, but all of these have limitations in relation to the potency, stability, selectivity, toxicity, and/or pharmacodyna- mic properties.
Such compounds have e.g. been disclosed in WO 98/19998, WO 00/34241 , US 6124305 (Novartis AG) and WO 99/38501 (Trustees of Tufts University).
Thus, there is a need for novel DPP-IV inhibitors that are superior with respect to one or more of the above listed properties, and which will be useful for the treatment of conditions, which may be regulated or normalised by inhibition of DPP-IV.
SUMMARY OF THE INVENTION
The present invention provides novel 2-substituted unsaturated heterocyclic compounds, wherein a nitrogen atom in the heterocyclic ring is attached via an amide bond or a peptide bond to an amino acid or an amino acid derivative. These compounds are potent and selective inhibitors of DPP-IV, and are effective in treating conditions that may be regulated or normalised via inhibition of DPP-IV. The invention also concerns pharmaceutical compositions comprising the compounds, a method of inhibiting DPP-IV comprising administering to a patient in need of such treatment a therapeutically effective amount thereof, the compounds for use as a pharmaceutical, and their use in a process for the preparation of a medicament for treating a condition which may be regulated or normalised via inhibition of DPP-IV.
DEFINITIONS
The term " DPP-IV" as used herein is intended to mean Dipeptidyl peptidase IV (EC 3.4.14.5; DPP-IV), also known as CD26. DPP-IV cleaves a dipeptide from the N terminus of a polypeptide chain containing a proline or alanine residue in the penultimate position. The term "treatment" is defined as the management and care of a patient for the purpose of combating the disease, condition, or disorder and includes the administration of a compound of the present invention to prevent the onset of the symptoms or complications, or alleviating the symptoms or complications, or eliminating the disease, condition, or disorder. The term "beta cell degeneration" is intended to mean loss of beta cell function, beta cell dysfunction, and death of beta cells, such as necrosis or apoptosis of beta cells.
The term "C1-C10 alkyl" as used herein, alone or in combination, refers to a straight or branched, saturated hydrocarbon chain having from 1-10 carbon atoms such as but not limited to e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, sec. Butyi, isobutyl, tert. Butyl, n-pentyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 4-methylpentyl, neopentyl, 2,2- dimethylpropyl and the like.
The term "C2-Cιo-alkenyl" used herein, alone or in combination, refers to a straight or branched, unsaturated hydrocarbon chain having from 2-10 carbon atoms and at least one double bond such as but not limited to vinyl, 1-propenyl, allyl, isopropenyl, n- butenyl, n-pentenyl and n-hexenyl and the like.
The term "C2-C10 alkynyl" as used herein, alone or in combination, refers to an unsaturated hydrocarbon chain having from 2-10 carbon atoms and at least one triple bond such as but not limited to -C≡CH, -C=CCH3, -CH2C=CH, -CH2-CH2-C=CH, - CH(CH3)C=CH and the like.
The term "Ci.io-alkoxy" as used herein, alone or in combination is intended to include those Cι-10-alkyl groups of the designated length in either a linear or branched or cyclic configuration linked through an ether oxygen having its free valence bond from the ether oxygen. Examples of linear alkoxy groups are methoxy, ethoxy, propoxy, butoxy, pentoxy and hexoxy. Examples of branched alkoxy are isoprpoxy, sec-butoxy, tert-butoxy, isopentoxy and isohexoxy. Examples of cyclic alkoxy are cyclopropyloxy, cyclobutyloxy, cyclopentyloxy and cyclohexyloxy.
The term "C3-C10 cycloalkyl" as used herein refers to a radical of one or more saturated cyclic hydrocarbon having from 3-10 carbon atoms such as but not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, adamantyl and the like.
The term "C3-C10 cycloalkane" as used herein refers to a saturated cyclic hydrocarbon having from 3-10 carbon atoms such as but not limited to cyclopropane, cyclobutane, cyclopentane, cyclohexane, adamantane and the like. The term "C5-C10 cycloalkenyl" as used herein refers to a radical of one or more cyclic hydrocarbon having at least one double bond having from 5-10 carbon atoms such as but not limited to cyclopentenyl, cyclohexenyl and the like
The term "aryl" as used herein includes carbocyclic aromatic ring systems. Aryl is also intended to include the partially hydrogenated derivatives of the carbocyclic systems. The term "heteroaryl" as used herein includes heterocyclic unsaturated ring systems containing one or more heteroatoms selected from nitrogen, oxygen and sulphur such as furyl, thienyl, pyrrolyl, heteroaryl is also intended to include the partially hydrogenated derivatives of the heterocyclic systems enumerated below. The terms "aryl" and "heteroaryl" as used herein refers to an aryl which can be optionally substituted or a heteroaryl which can be optionally substituted and includes phenyl, biphenyl, indenyl, naphthyl (1-naphthyl, 2-naphthyl), N-hydroxytetrazolyl, N- hydroxytriazolyl, N-hydroxyimidazolyl, anthracenyl (1-anthracenyl, 2-anthracenyl, 3- anthracenyl), thiophenyl (2-thienyl, 3-thienyl), furyl (2-furyl, 3-furyl) , indolyl, oxadiazolyl, isoxazolyl, quinazolinyl, fluorenyl, xanthenyl, , isoindanyl, benzhydryl, acridinyl, thiazolyl, pyrrolyl (2-pyrrolyl), pyrazolyl (3-pyrazolyl), imidazolyl (1-imidazolyl, 2-imidazolyl, 4- imidazolyl, 5-imidazolyl), triazolyl (1 ,2,3-triazol-l-yl, 1 ,2,3-triazol-2-yl 1 ,2,3-triazol-4-yl, 1 ,2,4-triazol-3-yl), oxazolyl (2-oxazolyl, 4-oxazolyl, 5-oxazolyl), thiazolyl (2-thiazolyl, 4- thiazolyl, 5-thiazolyl), pyridyl (2-pyridyl, 3-pyridyl, 4-pyridyl), pyrimidinyl (2-pyrimidinyl, 4- pyrimidinyl, 5-pyrimidinyl, 6-pyrimidinyl), pyrazinyl, py dazinyl (3- pyridazinyl, 4- pyridazinyl, 5-pyridazinyl), quinolyl (2-quinolyl, 3-quinolyl, 4-quinolyl, 5-quinolyl, 6-quinolyl, 7-quinolyl, 8-quinolyl), isoquinolyl (1-isoquinolyl, 3-isoquinolyl, 4-isoquinolyl, 5-isoquinolyl, 6-isoquinolyl, 7-isoquinolyl, 8-isoquinolyl), benzo[b]furanyl (2-benzo[b]furanyl, 3- benzo[b]furanyl, 4-benzo[b]furanyl, 5-benzo[b]furanyl, 6-benzo[b]furanyl, 7- benzo[b]furanyl), 2,3-dihydro-benzo[b]furanyl (2-(2,3-dihydro-benzo[b]furanyl), 3-(2,3- dihydro-benzo[b]furanyl), 4-(2,3-dihydro-benzo[b]furanyl), 5-(2,3-dihydro- benzo[b]furanyl), 6-(2,3-dihydro-benzo[b]furanyl), 7-(2,3-dihydro-benzo[b]furanyl), benzo[b]thiophenyl (2-benzo[b]thiophenyl, 3-benzo[b]thiophenyl, 4-benzo[b]thiophenyl, 5- benzo[b]thiophenyl, 6-benzo[b]thiophenyl, 7-benzo[b]thiophenyl), 2,3-dihydro- benzo[b]thiophenyl (2-(2,3-dihydro-benzo[b]thiophenyl), 3-(2,3-dihydro- benzo[b]thiophenyl), 4-(2,3-dihydro-benzo[b]thiophenyl), 5-(2,3-dihydro- benzo[b]thiophenyl), 6-(2,3-dihydro-benzo[b]thiophenyl), 7-(2,3-dihydro- benzo[b]thiophenyl), indolyl (1 -indolyl, 2-indolyl, 3-indolyl, 4-indolyl, 5-indolyl, 6-indolyl, 7- indolyl), indazole (1-indazolyl, 3-indazolyl, 4-indazolyl, 5-indazolyl, 6-indazolyl, 7- indazolyl), benzimidazolyl (1-benzimidazolyl, 2-benzimidazolyl, 4-benzimidazolyl, 5- benzimidazolyl, 6-benzimidazolyl, 7-benzimidazolyl, 8-benzimidazolyl), benzoxazolyl (1- benzoxazolyl, 2-benzoxazolyl), benzothiazolyl (1-benzothiazolyl, 2-benzothiazolyl, 4- benzothiazolyl, 5-benzothiazolyl, 6-benzothiazolyl, 7-benzothiazolyl), carbazolyl (1- carbazolyl, 2-carbazolyl, 3-carbazolyl, 4-carbazolyl), 5H-dibenz[b,f]azepine (5H- dibenz[b,f]azepin-1-yl, 5H-dibenz[b,f]azepine-2-yl, 5H-dibenz[b,f]azepine-3-yl, 5H- dibenz[b,f]azepine-4-yl, 5H-dibenz[b,f]azepine-5-yl), 10,11-dihydro-5H-dibenz[b,f]azepine (10,11-dihydro-5H-dibenz[b,f]azepine-1-yl, 10,11-dihydro-5H-dibenz[b,f]azepine-2-yl, 10,11 -dihydro-5H-dibenz[b,f]azepine-3-yl, 10,11 -dihydro-5H-dibenz[b,f]azepine-4-yl, 10,11 -dihydro-5H-dibenz[b,f]azepine-5-yl).
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides compounds of formula I
N
Formula I
wherein at least one of the bonds in the five-membered ring is a double bond;
B is any alpha or beta amino acid connected to the ring with an amide or peptide bond; or a salt thereof with a pharmaceutically acceptable acid or base.
In a preferred embodiment the invention provides compounds of formula II
Formula II
wherein at least one of the bonds in the five-membered ring is a double bond;
R2 is H; C1-C10 alkyl optionally substituted with one or more R4 independently; C2- C10 alkenyl optionally substituted with one or more R4 independently; C2-Cι0-alkynyl optionally substituted with one or more R4 independently; C3-C10-cycloalkyl optionally substituted with one or more R4 ndependently; C5-C1Q cycloalkenyl optionally substituted with one or more R4 independently; aryl optionally substituted with one or more R5 independently; or heteroaryl optionally substituted with one or more R5 independently;
R3 is H; C1-C10 alkyl optionally substituted with one or more R4 independently; C2- C10 alkenyl optionally substituted with one or more R4 independently; C2-Cι0-alkynyl optionally substituted with one or more R4 independently; C3-C10 cycloalkyl optionally substituted with one or more R4 independently; C5-C10 cycloalkenyl optionally substituted with one or more R4 independently; aryl optionally substituted with one or more R5 independently and/or fused to a C3-C10 cycloalkane; or heteroaryl optionally substituted with one or more R5 independently and/or fused to a C3-C10 cycloalkane;
R2 may be connected to R3 by a saturated or unsaturated bridge containing 1-3 carbon atoms, nitrogen atoms, oxygen atoms or sulphur atoms independently, or a valence bond, thus forming a ring, said ring may be fused to an aryl or heteroaryl, optionally substituted by one or more R5 independently;
R4 is cycloalkyl, aryl optionally substituted with one or more R5 independently; heteroaryl optionally substituted with one or more R5 independently; amino optionally substituted with one or more R6 independently; -SO-R6; -SO2-R6; -CO-R6; -COO-R6, - CONH-R6; -CON(R6)2; -O-R6; -S-R6; carboxy; acetamido; cyano; nitro; halogen; hydroxy; trifluoromethyl; trifluoromethoxy; sulfamoyl; carbamoyl; hydroxymethyl;
R5 is halogen, C1-C10 alkyl, C1-C10 alkoxy, C1-C10 alkylamino, C.-C10 dialkylamino, benzyl, benzyloxy, hydroxymethyl, nitro, trifluoromethyl, trifluoromethoxy, trifluoromethylthio, N-hydroxyimino, cyano; carboxy; acetamido; hydroxy; sulfamoyl, carbamoyl;
R6 is C1-C10 alkyl, C2-C10 alkenyl, C2-Cιo-alkynyl, C3-Cι0-cycloalkyl, C5-C10 cycloalkenyl where any one of said alkyl, alkenyl, alkynyl, cycloalkyl, or cykloalkenyl may optionally be substituted with aryl optionally substituted with one or more R5 independently or heteroaryl optionally substituted with one or more R5 independently; benzyl, phenethyl; aryl optionally substituted with one or more R5 independently; or heteroaryl optionally substituted with one or more R5 independently with the proviso that R2 and R3 cannot both be H; or a salt thereof with a pharmaceutically acceptable acid or base. In a preferred embodiment the invention provides compounds of formula III
Formula
wherein
R2 is H; C1-C10 alkyl optionally substituted with one or more R4 independently; C2- C10 alkenyl optionally substituted with one or more R4 independently; C2-Cι0-alkynyl optionally substituted with one or more R4 independently; C3-Cι0-cycloalkyl optionally substituted with one or more R4 independently; C5-C10 cycloalkenyl optionally substituted with one or more R4 independently; aryl optionally substituted with one or more R5 independently; or heteroaryl optionally substituted with one or more R5 independently;
R3 is H; C1-C10 alkyl optionally substituted with one or more R4 independently; C2- C10 alkenyl optionally substituted with one or more R4 independently; C2-Cι0-alkynyl optionally substituted with one or more R4 independently; C3-C10 cycloalkyl optionally substituted with one or more R4 independently; C5-C10 cycloalkenyl optionally substituted with one or more R4 independently; aryl optionally substituted with one or more R5 independently and/or fused to a C3-C10 cycloalkane; or heteroaryl optionally substituted with one or more R5 independently and/or fused to a C3-C10 cycloalkane; R2 may be connected to R3 by a saturated or unsaturated bridge containing 1-3 carbon atoms, nitrogen atoms, oxygen atoms, or sulphur atoms independently, or a valence bond, thus forming a ring, said ring may be fused to an aryl or heteroaryl, optionally substituted by one or more R5 independently;
R4 is cycloalkyl, aryl optionally substituted with one or more R5 independently; heteroaryl optionally substituted with one or more R5 independently; amino optionally substituted with one or more R6 independently; -SO-R6; -S02-R6; -CO-R6; -COO-R6, - CONH-R6; -CON(R6)2; -O-R6; -S-R6; carboxy; acetamido; cyano; nitro; halogen; hydroxy; trifluoromethyl; trifluoromethoxy; sulfamoyl; carbamoyl; hydroxymethyl; R is halogen, CrC10 alkyl, C1-C10 alkoxy, C1-C10 alkylamino, C1-C10 dialkylamino, benzyl, benzyloxy, hydroxymethyl, nitro, trifluoromethyl, trifluoromethoxy, trifluoromethylthio, N-hydroxyimino, cyano; carboxy; acetamido; hydroxy; sulfamoyl, carbamoyl; R6 is C1-C10 alkyl, C2-C10 alkenyl, C2-Cι0-alkynyl, C3-Cι0-cycloalkyl, C5-C10 cycloalkenyl where any one of said alkyl, alkenyl, alkynyl, cycloalkyl, or cykloalkenyl may optionally be substituted with aryl optionally substituted with one or more R5 independently or heteroaryl optionally substituted with one or more R5 independently; benzyl, phenethyl; aryl optionally substituted with one or more R5 independently; or heteroaryl optionally substituted with one or more R5 independently with the proviso that R2 and R3 cannot both be H; or a salt thereof with a pharmaceutically acceptable acid or base.
In another preferred embodiment, the invention provides compounds of formula IV
Formula IV
wherein at least one of the bonds in the five-membered ring is a double bond;
R2 is H; C1-C10 alkyl optionally substituted with one or more R4 independently; C2- C10 alkenyl optionally substituted with one or more R4 independently; C2-Cι0-alkynyl optionally substituted with one or more R4 independently; C3-Cι0-cycloalkyl optionally substituted with one or more R4 independently; C5-C10 cycloalkenyl optionally substituted with one or more R4 independently; aryl optionally substituted with one or more R5 independently; or heteroaryl optionally substituted with one or more R5 independently;
R3 is H; C1-C10 alkyl optionally substituted with one or more R4 independently; C2- C10 alkenyl optionally substituted with one or more R4 independently; C2-Cιo-alkynyl optionally substituted with one or more R4 independently; C3-Cι0 cycloalkyl optionally substituted with one or more R4 independently; C5-C10 cycloalkenyl optionally substituted with one or more R4 independently; aryl optionally substituted with one or more R5 independently and/or fused to a C3-C10 cycloalkane; or heteroaryl optionally substituted with one or more R5 independently and/or fused to a C3-C10 cycloalkane;
R2 may be connected to R3 or R7 by a saturated or unsaturated bridge containing 1-3 carbon atoms, nitrogen atoms, oxygen atoms, sulphur atoms independently, or a valence bond, thus forming a ring, said ring may be fused to an aryl or heteroaryl, optionally substituted by one or more R5 independently;
R4 is cycloalkyl; aryl optionally substituted with one or more R5 independently; heteroaryl optionally substituted with one or more R5 independently; amino optionally substituted with one or more R6 independently; -SO-R6; -SO2-R6; -CO-R6; -COO-R6, - CONH-R6; -CON(R6)2; -O-R6; -S-R6; carboxy; acetamido; cyano; nitro; halogen; hydroxy; trifluoromethyl; trifluoromethoxy; sulfamoyl; carbamoyl; hydroxymethyl;
R5 is halogen, C1-C10 alkyl, C1-C10 alkoxy, C1-C10 alkylamino, C1-C10 dialkylamino, benzyl, benzyloxy, hydroxymethyl, nitro, trifluoromethyl, trifluoromethoxy, trifluoromethylthio, N-hydroxyimino, cyano; carboxy; acetamido; hydroxy; sulfamoyl, carbamoyl; R6 is Cι-C10 alkyl, C2-C10 alkenyl, C2-Cι0-alkynyl, C3-Cιo-cycloalkyl, C5-C10 cycloalkenyl where any one of said alkyl, alkenyl, alkynyl, cycloalkyl, or cykloalkenyl may optionally be substituted with aryl optionally substituted with one or more R5 independently or heteroaryl optionally substituted with one or more R5 independently; benzyl, phenethyl; aryl optionally substituted with one or more R5 independently; or heteroaryl optionally substituted with one or more R5 independently;
R7 is H; C1-C10 alkyl optionally substituted with one or more R4 independently; C2- C10 alkenyl optionally substituted with one or more R4 independently; C2-Cι0-alkynyl optionally substituted with one or more R4 independently; C3-Cιo-cycloalkyl optionally substituted with one or more R4 independently; C5-C10 cycloalkenyl optionally substituted with one or more R4 independently; aryl optionally substituted with one or more R5 independently; heteroaryl optionally substituted with one or more R5 independently, halogen, C1-C10 alkoxy, C1-C10 alkylthio, C1-C10 alkylamino, C1-C10 dialkylamino, hydroxymethyl, nitro, trifluoromethyl, trifluoromethoxy, trifluoromethylthio, N- hydroxyimino, cyano; carboxy; acetamido; hydroxy; sulfamoyl, carbamoyl; with the proviso that the groups R2, R3, and R7 cannot all be H. or a salt thereof with a pharmaceutically acceptable acid or base.
In another preferred embodiment, the invention provides compounds of formula V
Formula V
wherein
R2 is H; C1-C10 alkyl optionally substituted with one or more R4 independently; C2-
C10 alkenyl optionally substituted with one or more R independently; C2-Cι0-alkynyl optionally substituted with one or more R4 independently; C3-Cιo-cycloalkyl optionally substituted with one or more R4 independently; C5-C10 cycloalkenyl optionally substituted with one or more R4 independently; aryl optionally substituted with one or more R5 independently; or heteroaryl optionally substituted with one or more R5 independently;
R3 is H; C1-C10 alkyl optionally substituted with one or more R4 independently; C2- C10 alkenyl optionally substituted with one or more R4 independently; C2-Cιo-alkynyl optionally substituted with one or more R4 independently; C3-C10 cycloalkyl optionally substituted with one or more R4 independently; C5-C10 cycloalkenyl optionally substituted with one or more R4 independently; aryl optionally substituted with one or more R5 independently and/or fused to a C3-C10 cycloalkane; or heteroaryl optionally substituted with one or more R5 independently and/or fused to a C3-C10 cycloalkane;
R2 may be connected to R3 or R7 by a saturated or unsaturated bridge containing 1-3 carbon atoms, nitrogen atoms, oxygen atoms, or sulphur atoms independently, or a valence bond, thus forming a ring, said ring may be fused to an aryl or heteroaryl, optionally substituted by one or more R5 independently;
R4 is cycloalkyl; aryl optionally substituted with one or more R5 independently; heteroaryl optionally substituted with one or more R5 independently; amino optionally substituted with one or more R6 independently; -SO-R6; -SO2-R6; -CO-R6; -COO-R6, - CONH-R6; -CON(R6)2; -O-R6; -S-R6; carboxy; acetamido; cyano; nitro; halogen; hydroxy; trifluoromethyl; trifluoromethoxy; sulfamoyl; carbamoyl; hydroxymethyl; R5 is halogen, C1-C10 alkyl, C1-C10 alkoxy, C1-C10 alkylamino, C1-C10 dialkylamino, benzyl, benzyloxy, hydroxymethyl, nitro, trifluoromethyl, trifluoromethoxy, trifluoromethylthio, N-hydroxyimino, cyano; carboxy; acetamido; hydroxy; sulfamoyl, carbamoyl;
R6 is C1-C10 alkyl, C2-C10 alkenyl, C2-Cιo-alkynyl, C3-C10-cycloalkyl, C5-C10 cycloalkenyl where any one of said alkyl, alkenyl, alkynyl, cycloalkyl, or cykloalkenyl may optionally be substituted with aryl optionally substituted with one or more R5 independently or heteroaryl optionally substituted with one or more R5 independently; benzyl, phenethyl; aryl optionally substituted with one or more R5 independently; or heteroaryl optionally substituted with one or more R5 independently R7 is H; C1-C10 alkyl optionally substituted with one or more R4 independently; C2-
C10 alkenyl optionally substituted with one or more R4 independently; C2-Cι0-alkynyl optionally substituted with one or more R4 independently; C3-Cι0-cycloalkyl optionally substituted with one or more R4 independently; C5-C10 cycloalkenyl optionally substituted with one or more R4 independently; aryl optionally substituted with one or more R5 independently; heteroaryl optionally substituted with one or more R5 independently, halogen, C1-C10 alkoxy, C.-C10 alkylthio, C1-C10 alkylamino, C1-C.0 dialkylamino, hydroxymethyl, nitro, trifluoromethyl, trifluoromethoxy, trifluoromethylthio, N- hydroxyimino, cyano; carboxy; acetamido; hydroxy; sulfamoyl, carbamoyl;
with the proviso that the groups R2, R3, and R7 cannot all be H. or a salt thereof with a pharmaceutically acceptable acid or base.
A further preferred embodiment is represented by the compounds of the invention wherein:
R2 is H; C1-C10 alkyl optionally substituted with R4; C2-C10 alkenyl optionally substituted with R4; C2-Cιo-alkynyl optionally substituted with R4; aryl optionally substituted with one or more R5 independently; or heteroaryl optionally substituted with one or more R5 independently;
Another preferred embodiment is represented by the compounds of the invention wherein R2 is H or C1-C10 alkyl optionally substituted with R4.
Another preferred embodiment is represented by the compounds of the invention wherein R2 is H.
Another preferred embodiment is represented by the compounds of the invention wherein:
R3 is H; C1-C10 alkyl optionally substituted with R4; C2-C10 alkenyl optionally substituted with R4; C2-Cιo-alkynyl optionally substituted with R4; C3-C10 cycloalkyl optionally substituted with R4; aryl optionally substituted with one or more R5 independently and/or fused to a C3-C10 cycloalkane; or heteroaryl optionally substituted with one or more R5 independently and/or fused to a C3-C10 cycloalkane;
Another preferred embodiment is represented by the compounds of the invention wherein:
R3 is H; C1-C10 alkyl optionally substituted with R4; or aryl optionally substituted with one or more R5 independently and/or fused to a C3-C10 cycloalkane.
Another preferred embodiment is represented by the compounds of the invention wherein R3 is C1-C10 alkyl optionally substituted with R4.
Another preferred embodiment is represented by the compounds of the invention wherein:
R4 is cycloalkyl; aryl optionally substituted with one or more R5 independently; heteroaryl optionally substituted with one or more R5 independently; -SO-R6; -S02-R6; - CO-R6; -COO-R6; -O-R6; -S-R6;
Another preferred embodiment is represented by the compounds of the invention wherein:
R4 is aryl optionally substituted with one or more R5 independently; heteroaryl optionally substituted with one or more R5 independently; -CO-R6; -COO-R6; -O-R6; -S- R6;
Another preferred embodiment is represented by the compounds of the invention wherein R4 is aryl optionally substituted with one or more R5 independently;
Another preferred embodiment is represented by the compounds of the invention wherein R4 is -COO-R6, -O-R6, or -S-R6;
Another preferred embodiment is represented by the compounds of the invention wwhheerreeiinn RR55 iiss hhaallooggeenn,, CC11--CC1100 alkyl, C1-C10 alkoxy, Cι-Cι0 alkylamino, C1-C10 dialkylamino, benzyl, or benzyloxy.
Another preferred embodiment is represented by the compounds of the invention wherein R5 is halogen, C1-C10 alkyl, or C1-C10 alkoxy.
Another preferred embodiment is represented by the compounds of the invention wherein R6 is C1-C10 alkyl, C2-C10 alkenyl optionally substituted with R4; C2-Cιo-alkynyl optionally substituted with R4; benzyl, aryl optionally substituted with one or more R5 independently, or heteroaryl optionally substituted with one or more R5 independently.
Another preferred embodiment is represented by the compounds of the invention wherei nn RR66 iiss C1-C10 alkyl, benzyl, or aryl optionally substituted with one or more R5 independently.
The most preferred compounds of formula I wherein B represents an alpha-amino acid are the following:
(S,S) 1 -(2-Amino-propionyl)-2,5-dihydro-1 H-pyrrole-2-carbonitrile (S,S) 1-(2-Amino-butyryl)- 2,5-dihydro-1 H-pyrrole-2-carbonithle (S,S) 1-(2-Amino-3-methyl-butyryl)-2,5-dihydro-1 H-pyrrole-2-carbonitrile (S,S) 1 -(2-Amino-3,3-dimethyl-butyryl)-2,5-dihydro-1 H-pyrrole-2-carbonitrile (S,S) 1 -(2-Amino-4-methyl-pent-4-enoyl)-2,5-dihydro-1 H-pyrrole-2-carbonitrile (S,S) 1 -(2-Amino-3,3-diethyl-pentanoyl)-2,5-dihydro-1 H-pyrrole-2-carbonitrile (S,S) 1 -(2-Amino-2-cyclopentylacetyl)-2,5-dihydro-1 H-pyrrole-2-carbonitrile -Amino-2-cyclohexylacetyl)-2,5-dihydro-1 H-pyrrole-2-carbonitrile -Amino-2-cycloheptylacetyl)-2,5-dihydro-1 H-pyrrole-2-carbonitrile -Amino-2-bicyclo[2.2.2]oct-1-yl-acetyl)-2,5-dihydro-1 H-pyrrole-2-carbonitrile -Adamantan-1-yl-2-amino-acetyl)-2,5-dihydro-1 H-pyrrole-2-carbonitrile -Amino-2-phenylacetyl)-2,5-dihydro-1 H-pyrrole-2-carbonitrile -Amino-2-(2,6 dimethylphenyl)acetyl)-2,5-dihydro-1 H-pyrrole-2-carbonithle -Amino-3,3-diphenyl-propionyl)-2,5-dihydro-1 H-pyrrole-2-carbonitrile -Amino-(3(R)-methylpentanoyl)-2,5-dihydro-1 H-pyrrole-2-carbonitrile -Amino-(4-methylpentanoyl)-2,5-dihydro-1 H-pyrrole-2-carbonitrile ,6-Diamino-hexanoyl)-2,5-dihydro-1 H-pyrrole-2-carbonitrile -Amino-6-dibenzylamino-hexanoyl)-2,5-dihydro-1 H-pyrrole-2-carbonitrile -Amino-6-benzylamino-hexanoyl)-2,5-dihydro-1 H-pyrrole-2-carbonitrile S,S) [5-Amino-6-(2-cyano-2,5-dihydro-pyrrol-1 -yl)-6-oxo-hexyl]-carbamic acid-tert-butyl ester
S,S) [5-Amino-6-(2-cyano-2,5-dihydro-pyrrol-1-yl)-6-oxo-hexyl]-carbamic acid 9-H- luoren-9-ylmethyl ester
S,S) 4-Amino-5-(2-cyano-2,5-dihydro-pyrrol-1-yl)-5-oxo-pentanoic acid amide S,S) 4-Amino-5-(2-cyano-2,5-dihydro-pyrrol-1-yl)-5-oxo-pentanoic acid benzylamide S,S) 4-Amino-5-(2-cyano-2,5-dihydro-pyrrol-1-yl)-5-oxo-pentanoic acid benzyl ester S,S) 4-Amino-5-(2-cyano-2,5-dihydro-pyrrol-1-yl)-5-oxo-pentanoic acid-tert-butyl ester S,S) 1 -(2-Amino-3-benzyloxy-propionyl)-2,5-dihydro-1 H-pyrrole-2-carbonithle S,S) 1 -(2-Amino-(4-methylsulfanyl-butyryl)-2,5-dihydro-1 H-pyrrole-2-carbonithle S,S) 1 -(2-Amino-(3-phenylpropionyl)-2,5-dihydro-1 H-pyrrole-2-carbonitrile S,S) 1 -(Pyrrolidine-2-carbonyl)-2,5-dihydro-1 H-pyrrole-2-carbonitrile S,S) 6-{2-[2-(2-Cyano-2,5-dihydro-pyrrol-1-yl)-2-oxo-ethylamino]-ethylamino}-nicotino- nitrile
S,S) 1 -{2-[2-(5-Chloro-pyhdin-2-ylamino)-ethylamino]-acetyl}-2,5-dihydro-1 H-pyrrole-2- carbonit le
S,S) 1 -{2-[2-(5-Trifluoromethyl-pyridin-2-ylamino)-ethylamino]-acetyl}-2,5-dihydro-1 H- pyrrole-2-carbonitrile
S,S) 1-[2-(1-Hydroxymethyl-cyclopentyIamino)-acetyl]-2,5-dihydro-1 H-pyrrole-2-carbo- nitrile S,S) 1 -{2-[2-(5-Nitro-pyridin-2-ylamino)-ethylamino]-acetyl}-2,5-dihydro-1 H-pyrrole-2-car- bonitrile
(S.S) 1-[2-(3-lsopropoxy-propylamino)-acetyl]- 2,5-dihydro-1 H-pyrrole-2-carbonitrile,
The most preferred compounds of formula I wherein B represents a beta-amino acid are the following: 1 -(Piperidine-3-carbonyl)-2,5-dihydro-1 -H-pyrrole-2-S-carbonitrile
1-(cis(2-Amino-cyclopenanecarbonyl))-2,5-dihydro-1-H-pyrrole-2-S-carbonitrile 1-(3-R-Amino-5-phenyl-pentanoyl)-2,5-dihydro-1-H-pyrrole-2-S-carbonit le 1-(3-S-Amino-5-phenyl-pentanoyl)-2,5-dihydro-1-H-pyrrole-2-S-carbonitrile 1-(3-S-Amino-4-phenyl-butyryl)-2,5-dihydro-1-H-pyrrole-2-S-carbonitrile 1 -(3-R-Amino-3-phenyl-propionyl)-2,5-dihydro-1 -H-pyrrole-2-S-carbonitrile
1-(Morpholine-2-carbonyl)-2,5-dihydro-1-H-pyrrole-2-S-carbonitrile 1-(3-R-Amino-6-phenyl-hex-5-enoyl)-2,5-dihydro-1-H-pyrrole-2-S-carbonitrile 1-(3-R-Amino-4-benzo[b]thiophen-2-yl-butyryl)-2,5-dihydro-1-H-pyrrole-2-S- carbonitrile 1 -(3-R-amino-4-pyridin-3-yl-butyryl)-2,5-dihydro-1 -H-pyrrole-2-S-carbonitrile
1-[3-S-Amino-4-(4-benzyloxy-phenyl)-butyryl]-2,5-dihydro-1-H-pyrrole-2-S- carbonitrile
1-[2-S-Pyrolidin-2-yl-acetyl)-2,5-dihydro-1-H-pyrrole-2-S-carbonitrile 1-[4-(2-Chloro-phenyl)-pyrrolidine-3-carbonyl]-2,5-dihydro-1-H-pyrrole-2-S- carbonitrile
1-(4-R-Phenyl-pyrrolidine-3-S-carbonyl)-2,5-dihydro-1-H-pyrrole-2-S-carbonithle or a salt thereof with a pharmaceutically acceptable acid or base.
The invention also relates to methods for preparing the above-mentioned compounds. These methods comprise (1) and (2) described below:
(1) Reacting an alpha amino acid or a beta-amino acid, suitably amino-protected with a standard protecting group such as Boc-, Fmoc-, CBz- or the like, with a 2- carbamoyl substituted unsaturated heterocyclic compound of formula VI,
Formula VI
under standard peptide coupling conditions to give an amide product; dehydrating the carbamoyl functionality of this material using standard dehydrating agents such as phosphorous oxycloride in pyridine or DMF, or trifluoroacetic acid anhydride, or the bromine/triphenylphospine adduct to give the nitrile, and to deprotect the amino group using standard chemical transformations to give the compounds of the invention. (2) Reacting a 2-carbamoyl substituted unsaturated heterocyclic compound of formula VI,
Formula VI
with an alpha-halogenated carboxylic acid chloride, bromide, or anhydride to give a compound of formula VII,
Formula VII
dehydrating the carbamoyl functionality of this material using standard dehydrating agents such as phosphorous oxycloride in pyridine or DMF, or trifluoroacetic acid anhydride, or the bromine/triphenylphospine adduct to give the nitrile, and reacting the nitrile compound with an appropriately substituted amine to give the compounds of the invention.
The compounds of the present invention may be prepared in the form of pharmaceutically acceptable salts, especially acid-addition salts, including salts of organic acids and mineral acids. Examples of such salts include salts of organic acids such as formic acid, fumaric acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, succinic acid, malic acid, tartaric acid, citric acid, benzoic acid, salicylic acid and the like. Suitable inorganic acid-addition salts include salts of hydrochloric, hydrobromic, sulphuric and phosphoric acids and the like. Further examples of pharmaceutically acceptable inorganic or organic acid addition salts include the pharmaceutically acceptable salts listed in Journal of Pharmaceutical Science, 66, 2 (1977) which are known to the skilled artisan.
Also intended as pharmaceutically acceptable acid addition salts are the hydrates which the present compounds are able to form.
The acid addition salts may be obtained as the direct products of compound synthesis. In the alternative, the free base may be dissolved in a suitable solvent containing the appropriate acid, and the salt isolated by evaporating the solvent or otherwise separating the salt and solvent.
The compounds of this invention may form solvates with standard low molecular weight solvents using methods known to the skilled artisan.
It is to be understood that the invention extends to all of the stereo isomehc forms of the claimed compounds, as well as the racemates.
A further aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for treating a condition which may be regulated or normalised via inhibition of DPP-IV.
Another aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for treatment of metabolic disorders.
Another aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for blood glucose lowering.
Another aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for treatment of Type II diabetes
Another aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for the treatment of impaired glucose tolerance (IGT). Another aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for the treatment of impaired fasting glucose (IFG).
Another aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for prevention of hyperglycemia.
Another aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for delaying the progression of impaired glucose tolerance (IGT) to Type II diabetes.
Another aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for delaying the progression of non-insulin requiring Type II diabetes to insulin requiring Type II diabetes. Another aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for increasing the number and/or the size of beta cells in a mammalian subject.
Another aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for treatment of beta cell degeneration, in particular apoptosis of beta cells.
Another aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for the treatment of disorders of food intake.
Another aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for the treatment of obesity.
Another aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for appetite regulation or induction of satiety.
Another aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for the treatment of dyslipidemia.
Another aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for treatment of functional dyspepsia, in particular irritable bowel syndrome.
A further aspect of the invention is a method for treating the conditions mentioned above by administering to a subject in need thereof an effective amount of a compound of the invention.
Combination treatments
The invention furthermore relates to the use of a compound according to the present invention for the preparation of a medicament for use in the treatment of diabetes in a regimen which additionally comprises treatment with another antidiabetic agent.
In one embodiment of this invention, the antidiabetic agent is insulin or GLP-1 or any analogue or derivative thereof.
In another embodiment the antidiabetic agent is a non-peptidyl hypoglycaemic agent, preferably an oral hypoglycaemic agent.
Oral hypoglycaemic agents are preferably selected from the group consisting of sulfonylureas, non-sulphonylurea insulin secretagogues, biguanides, thiazolidinediones, alpha glucosidase inhibitors, glucagon antagonists, GLP-1 agonists, potasium channel openers, insulin sensitizers, hepatic enzyme inhibitors, glucose uptake modulators, compounds modifying the' lipid metabolism, compounds lowering food intake, and agents acting on the ATP-dependent potassium channel of the β-cells.
Among the sulfonylureas, tolbutamide, glibenclamide, glipizide and gliclazide are preferred.
Among the non-sulphonylurea insulin secretagogues, repaglinide and nateglinide are preferred.
Among the biguanides, metformin is preferred.
Among the thiazolidinediones, troglitazone, rosiglitazone and ciglitazone are preferred. Among the glucosidase inhibitors, acarbose is preferred.
Among the agents acting on the ATP-dependent potassium channel of the β-cells the following are preferred: glibenclamide, glipizide, gliclazide, repaglinide.
Pharmaceutical compositions
In another aspect, the present invention includes within its scope pharmaceutical compositions comprising, as an active ingredient, at least one compound of the invention which inhibits the enzymatic activity of DPP-IV or a pharmaceutically acceptable salt or prodrug or hydrate thereof together with a pharmaceutically acceptable carrier or diluent. Pharmaceutical compositions containing a compound of the invention of the present invention may be prepared by conventional techniques, e.g. as described in Remington: The Science and Practise of Pharmacy, 9th Fri 1995. The compositions may appear in conventional forms, for example capsules, tablets, aerosols, solutions, suspensions or topical applications. Typical compositions include a compound of the invention which inhibits the enzymatic activity of DPP-IV or a pharmaceutically acceptable basic addition salt or prodrug or hydrate thereof, associated with a pharmaceutically acceptable excipient which may be a carrier or a diluent or be diluted by a carrier, or enclosed within a carrier which can be in the form of a capsule, sachet, paper or other container. In making the compositions, conventional techniques for the preparation of pharmaceutical compositions may be used. For example, the active compound will usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier which may be in the form of a ampoule, capsule, sachet, paper, or other container. When the carrier serves as a diluent, it may be solid, semi-solid, or liquid material which acts as a vehicle, excipient, or medium for the active compound. The active compound can be adsorbed on a granular solid container for example in a sachet. Some examples of suitable carriers are water, salt solutions, alcohols, polyethylene glycols, polyhydroxyethoxylated castor oil, peanut oil, olive oil, gelatine, lactose, terra alba, sucrose, dextrin, magnesium carbonate, sugar, cyclodextrin, amylose, magnesium stearate, talc, gelatine, agar, pectin, acacia, stearic acid or lower alkyl ethers of cellulose, silicic acid, fatty acids, fatty acid amines, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, polyoxyethylene, hydroxymethylcellulose and polyvinylpyrrolidone. Similarly, the carrier or diluent may include any sustained release material known in the art, such as glyceryl monostearate or glyceryl distearate, alone or mixed with a wax. The formulations may also include wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents or flavouring agents. The formulations of the invention may be formulated so as to provide quick, sustained, or delayed release of the active ingredient after administration to the patient by employing procedures well known in the art.
The pharmaceutical compositions can be sterilized and mixed, if desired, with auxiliary agents, emulsifiers, salt for influencing osmotic pressure, buffers and/or colouring substances and the like, which do not deleteriously react with the active compounds. The route of administration may be any route, which effectively transports the active compound of the invention which inhibits the enzymatic activity of DPP-IV to the appropriate or desired site of action, such as oral, nasal, pulmonary, buccal, subdermal, intradermal, transdermal or parenteral e.g. rectal, depot, subcutaneous, intravenous, intraurethral, intramuscular, intranasal, ophthalmic solution or an ointment, the oral route being preferred.
If a solid carrier is used for oral administration, the preparation may be tabletted, placed in a hard gelatin capsule in powder or pellet form or it can be in the form of a troche or lozenge. If a liquid carrier is used, the preparation may be in the form of a syrup, emulsion, soft gelatin capsule or sterile injectable liquid such as an aqueous or non-aqueous liquid suspension or solution.
For nasal administration, the preparation may contain a compound of the invention which inhibits the enzymatic activity of DPP-IV, dissolved or suspended in a liquid carrier, in particular an aqueous carrier, for aerosol application. The carrier may contain additives such as solubilizing agents, e.g. propylene glycol, surfactants, absorption enhancers such as lecithin (phosphatidylcholine) or cyclodextrin, or preservatives such as parabenes.
For parenteral application, particularly suitable are injectable solutions or suspensions, preferably aqueous solutions with the active compound dissolved in polyhydroxylated castor oil.
Tablets, dragees, or capsules having talc and/or a carbohydrate carrier or binder or the like are particularly suitable for oral application. Preferable carriers for tablets, dragees, or capsules include lactose, corn starch, and/or potato starch. A syrup or elixir can be used in cases where a sweetened vehicle can be employed.
A typical tablet which may be prepared by conventional tabletting techniques may contain:
Core:
Active compound (as free compound or salt thereof) 250 mg
Colloidal silicon dioxide (Aerosil)® 1.5 mg Cellulose, microcryst. (Avicel)® 70 mg
Modified cellulose gum (Ac-Di-Sol)® 7.5 mg
Magnesium stearate Ad.
Coating: HPMC approx. 9 mg
*Mywacett 9-40 T approx. 0.9 mg
*Acylated monoglyceride used as plasticizer for film coating.
The compounds of the invention may be administered to a mammal, especially a human in need of such treatment, prevention, elimination, alleviation or amelioration of the various diseases as mentioned above, e.g. type II diabetes, IGT, IFG, obesity, appetite regulation or as a blood glucose lowering agent, and especially type II diabetes. Such mammals include also animals, both domestic animals, e.g. household pets, and non-domestic animals such as wildlife.
The compounds of the invention are effective over a wide dosage range. For example, in the treatment of adult humans, dosages from about 0.05 to about 1000 mg, preferably from about 0.1 to about 500 mg, per day may be used. A most preferable dosage is about 0.5 mg to about 250 mg per day. In choosing a regimen for patients it may frequently be necessary to begin with a higher dosage and when the condition is under control to reduce the dosage. The exact dosage will depend upon the mode of administration, on the therapy desired, form in which administered, the subject to be treated and the body weight of the subject to be treated, and the preference and experience of the physician or veterinarian in charge. Generally, the compounds of the present invention are dispensed in unit dosage form comprising from about 0.05 to about 1000 mg of active ingredient together with a pharmaceutically acceptable carrier per unit dosage.
Usually, dosage forms suitable for oral, nasal, pulmonal or transdermal administration comprise from about 0.05 mg to about 1000 mg, preferably from about 0.5 mg to about 250 mg of the compounds admixed with a pharmaceutically acceptable carrier or diluent.
The invention also encompasses prodrugs of a compound of the invention which on administration undergo chemical conversion by metabolic processes before becoming active pharmacological substances. In general, such prodrugs will be functional derivatives of a compound af the invention which are readily convertible in vivo into a compound af the invention. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985.
The invention also encompasses active metabolites of a compound of the invention.
Methods for measuring the activity of compounds which inhibit the enzymatic activity of CD26/DPP-IV
Summary.
Chemical compounds are tested for their ability to inhibit the enzyme activity of purified CD26/DPP-IV. Briefly, the activity of CD26/DPP-IV is measured in vitro by its ability to cleave the synthetic substrate Gly-Pro-p-nitroanilide (Gly-Pro-pNA). Cleavage of Gly-Pro-pNA by DPP-IV liberates the product p-nitroanilide (pNA), whose rate of appearance is directly proportional to the enzyme activity. Inhibition of the enzyme activity by specific enzyme inhibitors slows down the generation of pNA. Stronger interaction between an inhibitor and the enzyme results in a slower rate of generation of pNA. Thus, the degree of inhibition of the rate of accumulation of pNA is a direct measure of the strength of enzyme inhibition. The accumulation of pNA is measured spectrophotometrically. The inhibition constant, Ki, for each compound is determined by incubating fixed amounts of enzyme with several different concentrations of inhibitor and substrate.
Materials: The following reagents and cells are commercially available:
Porcine CD26/DPP-IV (Sigma D-7052), Gly-Pro-pNA (Sigma G0513).
Assay buffer: 50 mM Tris pH7.4, 150 mM NaCI, 0,1% Triton X-100.
Gly-Pro-pNA cleavage-assay for CD26; The activity of purified CD26/DPP-IV is assayed in reactions containing:
70 ul assay buffer
10 ul inhibitor or buffer
10 ul substrate (Gly-Pro-pNA from a 0.1 M stock solution in water) or buffer 10 ul enzyme or buffer
Reactions containing identical amounts of enzyme, but varying concentrations of inhibitor and substrate, or buffer as control, are set up in parallel in individual wells of a
96-well ELISA plate. The plate is incubated at 25°C and absorbance is read at 405 nm after 60 min incubation. The inhibitor constants are calculated by nonlinear regression hyperbolic fit and the result is expressed as inhibition constant (Ki) in nM.
Diabetes model
The Zucker Diabetic Fatty (ZDF) rat model can be used to investigate the effects of the compounds of the invention on both the treatment and prevention of diabetes as rats of this sub-strain are initially pre-diabetic although develop severe type 2 diabetes characterised by increased HbA1c levels over a period of 6 weeks. The same strain can be used to predict the clinical efficacy of other anti-diabetic drug types. For example, the model predicts the potency and limited clinical efficacy of thiazolidinedione insulin sensitiser compounds.
EXAMPLES
A further detailed description of the invention is given with reference to the following examples. Example 1
(S,S) 1-(7-Aminn-3r3-dim thyl-hιιtyryl)-? 5-dihydro-1 H-pyrrole-?-carhnnitrile (1 .
(S)-2-Amino-Λ/-tert-butyloxycarbonyl-3,3-dimethylbutyric acid (308 mg, 1.33 mmol) was dissolved in 3 ml of dichloromethane and 1-hydroxy-7-azabenzotriazole (HOAT) (180 mg, 1.33 mmol) and 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide, hydrochloride (EDAC) (258 mg, 1.35 mmol) was added. The mixture was stirred at room temperature for 30 minutes, and then (S) 2,5-dihydro-1H-pyrrole-2-carboxylic acid amide, (150 mg, 1.33 mmol) and diisopropylethylamine (0.46 ml, 2.68 mmol) were added. The reaction mixture was stirred at room temperature for 20 hours. The solvent was evaporated and the crude product was purified by preparative HPLC, using acetonitrile /water as the eluent. Fractions containing the product were collected and the solvents were evaporated, to afford 200 mg of (S,S) [1-(2-Carbamoyl-2,5-dihydro-pyrrole-1- carbonyl)-2,2-dimethyl-propyl]-carbamic acid tert-butyl ester (2). Oil, 47% yield. 1H-NMR (CDCI3, 200 MHz) δ: 1.03 (s, 9H); 1.42 (s, 9H); 4.29 (d, 1 H); 4.36-4.50 (m, 1 H); 4.62-4.73 (m, 1 H); 5.25-5.33 (m, 2H); 5.85-6.00 (m, 3H); 6.88 (br. s, 1 H).
(175 mg, 0.54 mmol) of (2) was dissolved in 4 ml of pyridine and the mixture was cooled to 0°C. Phosphorus oxychloride (0.2 ml, 2.15 mmol) was added dropwise and after 10 minutes of stirring the reaction mixture was poured into 20 ml of ice water and the organic material was extracted into 5 x 10 ml of ethyl acetate. The combined organic extract was washed with 2 x 20 ml of water, 1 x 20 ml of brine and dried over magnesium sulphate. The solvent was evaporated to afford 140 mg of (S,S) [1-(2-Cyano-2,5-dihydro- pyrrole-1-carbonyl)-2,2-dimethyl-propyl]-carbamic acid tert-butyl ester (3). Oil, 85 % yield.
1H-NMR (CDCI3, 200 MHz) δ: 1.05 (s, 9H); 1.42 (s, 9H); 4.22 (d, 1 H); 4.39-4.53 (m, 1 H); 4.65-4.77 (m, 1 H); 5.30 (d, 1 H); 5.41-5.48 (m, 1 H); 5.83-5.90 (m, 1 H); 6.09-6.15 (m, 1 H).
(140 mg, 0.46 mmol) of (3) was dissolved in 0.5 ml of dichloromethane and the mixture was cooled to 0°C. 0.5 ml of trifluoroacetic acid was added and the reaction mixture was stirred at 0°C for 1 hour. The solvent was evaporated and the crude product was purified by preparative HPLC, using acetonitrile /water as the eluent. Fractions containing the product were collected and the solvent was evaporated, to afford 25 mg of the title compound (1 ) as the trifluoroacetic acid salt. Oil, 17% yield. 1H-NMR (MeOH, 200
MHz) δ: 1.20 (s, 9H); 4.08 (s, 1 H); 4.46-4.70 (m, 2H); 5.56-5.62 (m, 1 H); 5.95-6.02 (m,
1 H); 6.22-6.29 (m, 1 H). LC-MS, m/z: 208.4 (M+1 )
The following compounds were prepared essentially by the route outlined in example 1 , however, most compounds were also purified by preparative HPLC after the dehydration step.
(S.S) 1-(?-Aminn-4-methyl-pent-4-ennyl)-?.5-dihyd -1 H-pyrrolR-?-r.arhnnitrile (2. (29 mg) LC-MS (El), m/z: 206 (M+1 ). Prepared from (S) 2-tert- Butoxycarbonylamino-4-methyl-pent-4-enoic acid. (S,S) 1-(Pyrroliriine-?-carbonyl)-2,5-dihydro-1 H-pyrrole-2-carbQnitrile (3)
(30 mg) 1 H-NMR (CDCI3, 200MHz) δ: 6.13 (d, 1 H); 5.90 (d, 1 H); 5.50 (s, 1 H); 4.78 (s, 1 H); 4.46 (m, 2H); 3.53 (s, 2H); 2.52 (s, 1 H); 2.18 (m, 3H); 1.4 (m, 1 H). LC-MS (El), m/z: 192 (M+1 ). Prepared from N-Boc-proline. (S.S) 1-(?-Amino-3-phenyl-prnpinnyl .-? 5-rlihyrirn-1 H-pyrrnle-?-carhnnitrilR (4)
(27 mg).1H-NMR (CDCI3, 200MHz) δ: 7.30 (m, 5H); 5.85 (dd, 1H); 5.70 (dd, 1H); 5.38 (m, 1H); 3.33 (dd, 1H); 4.2 (dd, 1H); 3.33, (dd, 1H); 3.15 (dd, 1H); 2.88 (dd, 1H). LC- MS (El), m/z: 242 (M+1). Prepared from N-Boc-Phenylalanine. (S.S.1-(?-Aminn-4-methyl-pRntanoyl)-2r5-dihydro-1 H-pyrrole-2-carhnnitrile (5.
(66 mg).1H-NMR (CDCI3, 200MHz) δ: 6.17 (dd, 1H); 5.90 (dd, 1H); 5.50 (m, 1H); 4.63 (dd, 1H); 4.38 - 4.28 (dd, 1H); 4.28 - 4.15 (dd, 1H); 1.92 - 1.54 (m, 3H); 1.00 (d, 6H). LC-MS (El), m/z: 208 (M+1). Prepared from N-Boc-Leucine.
(S,S) 1-[?-Aminn-3-(4-methnxy-phenyl)-propionyl]-2.5-dihydro-1H-pyrrole-2- carhnnitrile (6) (61 mg) 1H-NMR (CDCI3, 200MHz) δ: 7.15 (d, 2H); 6.76 (d, 2H); 5.85 (d, 1H); 5.68 (d, 1H); 5.30 (s, 1H); 4.38 (m, 1H); 4.25 (d, 1H); 3.73 (s, 3H); 3.32 (m, 1H); 3.12 (m, 2H). LC-MS (El), m/z: 272 (M+1). Prepared from (S) 2-tert- Butoxycarbonylamino-3-(4-methoxy-phenyl)-propionicacid.
(2S) 1 -(?'-Amino-?Nph nyl-aratyl)-?. S-dihydrn-1 H-pyrrnle-?-carbonitrile (7) (68 mg) 1H-NMR (CDCI3, 200MHz) δ: 7.48 (m, 5H); 5.57 (d, 1H); 5.75 (d, 1H);
5.43 d, 1H); 5.37 (s, 1H); 4.50 (dd, 1H); 3.75 (dd, 1H). LC-MS(EI), m/z: 228 (M+1). Prepared from (S)-Phenylglycine.
(S.S) 1-(?-Amino-3-ben7yloxy-propionyl)-2.5-dihydro-1 H-pyrrole-2-carbonitrile (8.
(61 mg) 1H-NMR (CDCI3, 200MHz) δ: 7.32 (m, 5H); 6.05 (dd, 1H); 5.82 (dd, 1H); 5.45 (dd, 1H); 4.68 - 4.42 (m, 4H); 4.15 (dd, 1H); 3.83 d, 2H). LC-MS(EI), m/z: 272 (M+1). Prepared from N-Boc-O-benzylserine.
(S.S) 1-(2-Amino-4-methylsulfanyl-hutyryl)-2.5-dihydro-1H-pyrrQle-2-carbonitrile
(65 mg) 1H-NMR (CDCI3, 200MHz) δ:6.15 (dd, 1H); 5.88 (dd, 1H); 5.52 (m, 1H); 4.58 (dd, 2H); 4.40 (t, 1H); 2.65 (m, 2H); 2.22 (m, 2H); 2.15 (s, 3H) LC-MS(EI), m/z: 226 (M+1). Prepared from N-Boc-methionine.
(S.S.1-(2-Amino-2-cyclohexyl-acetyl)-2.5-dihydro-1H-pyrrole-2-carhonitrile(10^
(116 mg) 1H-NMR (CDCI3, 200MHz) δ: 6.09 (d, 1H); 5.83 (d, 1H); 5.55 (s, 1H); 4.62 (d, 1H); 4.35 (d, 1H); 4.07 (d, 1H); 1.80 (m, 6H); 1.2 (m, 5H). LC-MS(EI), m/z: 234 (M+1). Prepared from (S) N-Boc-cyclohexylglycine
(PS.?'S,3'R) 1 -(P'-Amino- '-mPthyl-pentannyl .-7.5-dihyrirr.-1 H-pyrrole-?- carbonitrile (11)
(46 mg)1H-NMR (CDCI3, 200MHz) δ: 6.15 d(1H); 5.38 (d, 1H); 5.53 (s, 1H); 4.62 (d, 1H); 4.35 (d, 1H); 4.19 (d, 1H)1.96 (m, 1H); 1,60 (m, 1H); 1.38 (m, 1H); 1.1 (m, 6H). LC-MS(EI), m/z: 208 (M+1). Prepared from N-Boc-allo-isoleucine
C2S) 1-(7'-Amino-7'-naphthalen-1-yl-ar:Rtyl.-2,5-riihydrn-1H-pyrmle-2-carhonitrilf.
02) (8 mg) 1H-NMR (CDCI3, 200MHz) δ: 8.30 (d, 1H); 7.95 (t, 2H); 7.60 (m, 4H); 5.87
(m, 1H); 5.78 (m, 1H); 5.52 (m, 1/2H); 5.40 (m, 1/2H); 4.43 (m, 1H); 4.45 (m, 1H); 4.38 (m, 1H); 3.40 (m, 1H) LC-MS(EI), m/z: 277 (M). Prepared from (S) N-Boc-2-naphtylglycine
(2S,2'S,3'S),1-(2'-AminQ-3'-methyl-pentanoyl)-2,5-dihydro-1H-pyrrole-2- carbonitrile (13) (41 mg) 1H-NMR (CDCI3, 200MHz) δ: 6.12 (dd, 1H); 5.85 (dd, 1H); 5.48 (dd, 1H);
4.62 (dd, 1H); 4.35 (m, 1H); 4.05 (d, 1H); 2.0 (m, 1H); 1.61 (m, 1H); 1.27 (m, 1H); 1.07 (d, 3H); 0.97 (t, 3H). LC-MS(EI), m/z: 208 (M+1). Prepared from N-Boc-isoleucine
(S.S) 1-[?-Amino-3-(4-fli]orn-phenyl)-propionyl]-2.5-dihydro-1H-pyrrole-2- carhonitrile (14) (51 mg) 1H-NMR (CDCI3, 200MHz) δ: 7.25 (m, 2H); 7.15 (m, 2H); 5.90 (m,
1H); 5.74 (m, 1H); 5.38 (m, 1H); 4.25 (m, 2H); 3.17 (m, 3H). LC-MS(EI), m/z: 260 (M+1). Prepared from N-Boc-p-fluorophenylglycine.
3-Amino-4-(2-πyano-2,5-dihydrQ-pyrrol-1-yl)-4-oxo-butyrio acid methyl ester (1 ) (21 mg) LC-MS(ES), m/z: 224 (M+1).1H-NMR (MEOH, 200MHz) δ: 6.23 (m, 1H); 5.95 (m, 1H); 5.53 (m, 1H); 4.55 (m, 3H); 3.75 (s, 3H); 3.72 (t,1H); 3.18 - 2.79 (m, 3H). (SrS) 1 -(?-Amino-propionyl)-2.5-riihyrim-1 H-pyrrole-2-carhnnitrilfi (16. (13 mg) LC-MS(ES), m/z: 166 (M+1).1H-NMR (MEOH, 200MHz) δ: 6.25 (m, 1H); 5.98 (m, 1H); 5.54 (m, 1H); 4.50 (m, 2H); 4.27 (q, 1H); 1.57 (d, 3H).
3-Aminn-4-(2-cyano-2r5-dihyriro-pyrrnl-1-yl)-4-oyo-hιιtyric a iri hen7yl ester (17) (33 mg) LC-MS(ES), m/z: 300 (M+1).1H-NMR (MEOH, 200MHz) δ: 7.36 (m, 5H);
6.19 (m, 1H); 5.95 (m, 1H); 5.52 (m, 1H); 5.20 (s, 2H); 4.63 - 4.42 (m, 3H); 3.35 - 2.97 (m, 2H).
4-Aminn-5-(7-r:yann-2.5-riihyrim-pyrml-1-yl)-5-oxo-pentanoic acid hen7yl f-ster (l≤) (39 mg) LC-MS(ES), m/z: 314 (M+1).1H-NMR (MEOH, 200MHz) δ: 7.35 (m, 5H);
6.20 m, 1H); 5.95 (m, 1H); 5.53 (m, 1H); 5.18 (s, 2H); 4.45 (m, 2H); 4.35 (dd, 1H); 2.63 (t, 2H); 2.23 (m, 2H).
1-(2-Aminn-3r3-diphenyl-propionylV?,5-riihyrirn-1H-pyrrole-7-carhnnitrile (19) (1 mg) LC-MS(ES), m/z: 318 (M+1 )
(?S.?'R . 1-(?-Amino-3-methyl-3-methylsιιlfanyl-hιιtyryl)-2.5-dihyrirn-1 H-pyrrnlR-?- carhnnitrile (20)
(49 mg) LC-MS(ES), m/z: 240 (M+1 ). (S.S) 1-(2-Amino-3-cyclohexyl-pmpionyl)-?r5-riihydrn-1 H-pyrrnle-2-r:arhnnitrile
<21)
(30 mg) LC-MS(ES), m/z: 248 (M+1).
1 -[2-Amino-3-(1 -benzyl-1 H-imida7nl-4-yl)-propionyl]-2,5-dihydro-1 H-pyrrnlR-2- carhonitrile (27) (6 mg) LC-MS(ES), m/z: 322 (M+1 ).
(S,S) 1 -(?-Amino-3-merπaptn-3-mRthyl-hutyrylV2 R-dihyriro-1 H-pyrrnle-2- carbonitrile (23)
(23 mg) LC-MS(ES), m/z: 490 (M+Na+). 1 H-NMR (MEOH, 200MHz) δ: 7.24 (m, 15H); 6.23 (m, 1 H); 5.98 (m, 1 H); 5.57 (m, 1 H); 4.60 (m, 2H); 4.30 (s, 1 H); 1.58 (s, 3H); 1.52 (s, 3H).
1-p-Aminn-3-(4-mRthnxy-hen7ylsij|fanyl)-3-mRthyl-hMtyryl]-7.5-dihydrn-1 H- pyrrole-2-oarhonitrile (25)
(3 mg) LC-MS(ES), m/z: 346 (M+1 ).
(S,S) 1-p-Aminn-3-mRthyl-3-(4-mRthyl-hen7ylsiilfanyn-hιιtyryl]-2r5-dihydrn-1 H- pyrrnle-7-carhonitrilR (26)
(58 mg) LC-MS(ES), m/z: 330 (M+1 ). 1 H-NMR (MEOH, 200MHz) δ:7.32 (d, 2H); 7.13 (d, 2H); 6.20 (m, 1 H); 5.95 (m, 1 H); 5.52 (m, 1 H); 4.42 (m, 2H); 4.07 (s, 1 H); 3.90 (dd, 2H); 2.30 (s, 3H); 1.58 (s, 3H); 1.46 (s, 3H).
1 -[2-Amino-2-(4-fhjoro-phenyl)-acetyl]-2,5-riihydro-1 H-pyrrole-2-carbonitrile (27) (56 mg) LC-MS(ES), m/z: 246 (M+1 ). 1 H-NMR (MEOH, 200MHz) δ: 7.50 (m, 2H);
7.29 (m, 2H); 6.12 (m, 1 H); 5.92, (m, 1 H); 5.58 (m, 1 H); 5.40 (s, 1 H); 4.50 (dd, 1 H); 3.75 (m, 1 H).
(S.S) 1-(2-Aminn-7-inrian-4-yl-acRtyl)-? 5-riihyriro-1 H-pyrrole-2-carhonitrile (28)
(65 mg) LC-MS(ES), m/z: 268 (M+1 ). 1 H-NMR (MEOH, 200MHz) δ:7.20 (m, 3H); 6.23 (m, 1 H); 5.97 (m, 1 H); 5.56 (m, 1 H); 4.53 (m, 2H); 4.48 (s, 1 H); 3.20 - 2.96 (m, 6H).
(S.S) 1-(2-Amino-3-methyl-bMtyryl)-2,5-riihyrirn-1 H-pyrrolR-7-r-.arhnnitrilR (29)
(42 mg) LC-MS(ES), m/z: 195 (M+1 ). 1 H-NMR (MEOH, 200MHz) δ: 6.05 (m, 1 H); 5.89 (m, 1 H); 5.21 (m, 1 H); 4.52 - 4.38 (m, 2H); 4.15 - 4.00 (m, 1 H); 2.50 - 2.15 (m, 1H); 1.18d, 3H); 1.08 (d,3H).
1 -(5r5-Dimethyl-thia7θlidine-4-carhnnyl)-25-rlihydrn-1 H-pyrrole-P-πarhnnitrile (30) (115 mg) LC-MS(ES), m/z: 238 (M+1),
1 -(1 -Amino-cyr.lopropanecarhnnyl)-2,5-riihyrim-1 H-pyrrole-2-carhnnitrilR (31 ) (45 mg) LC-MS(ES), m/z: 178 (M+1)
(SrS) 1-(?-Amino-3-phenyl-propionyl)-2.5-dihyrim-1H-pyrrole-2-carhonitrile (32) (57 mg) LC-MS(ES), m/z: 242 (M+1).1H-NMR (MEOH, 200MHz) δ:7.34 (s, 5H);
5.95 (m, 1H); 5.83 (m, 1H); 5.45 (m, 1H); 4.45 (m, 1H); 4.25 (m, 1H); 3.33 - 3.00 (m, 3H). 1-(7-Amino-hutyryl)-?r5-dihydro-1H-pyrrolR-?-r.arhnnitrile(33)
(60 mg) LC-MS(ES), m/z: 180 (M+1).1H-NMR (MEOH, 200MHz) δ:6.25 (m, 1H);
5.96 (m, 1H); 5.55 (m, 1H); 4.50 (m, 2H); 4.22 (t, 1H); 2.00 (m, 2H); 1.18 (t, 3H).
1 -[2-Amino-3-(1 H-inriol-3-yl )-propionyl]-7.5-riihyriro-1 H-pyrrole-2-carhonitrilR (34)
(53 mg) LC-MS(ES), m/z: 281 (M+1). 1H-NMR (MEOH, 200MHz) δ: 7.70 - 7.03 (m, 5H); 5.90 (m, 1H); 5.80 (m, 1H); 5.45 (m, 1H); 4.42 (m, 1H); 4.20 (m, 1H); 3.45 -
3.15 (m,3H).
(S,S) 1-(PipRridine-2-carbonyl)-2.5-dihydro-1H-pyrrole-2-carbonitrile (35)
(177 mg) 1H-NMR (MEOH, 300MHz) δ: 6.25 (m, 1H); 5.98 (m, 1H); 5.53 (m, 1H); 4.49 (m, 2H); 4.15 (m, 1H); 3.43 (m, 1H); 3.08 (m, 1H); 2.29 (m, 1H); 1.95 (m, 2H); 1.71 (m, 3H).
(S,S) 1 -(1 ,2,3r4-Tetrahydro-isoquinoline-3-carbonyl)-2t5-dihydro-1 H-pyrrole-2- carbonitrile (36)
(357 mg).1H-NMR (MEOH, 300MHz) δ: 7.30 (m, 4H); 6.28 (m, 1H); 6.01 (m, 1H); 5.60 (m, 1H); 4.63-4.42 (m, 5H); 3.52 (dd, 1H); 3.19 (dd, 1H). 1 -(?-Aminn-cyclnpRntanRcarbonyn-2r5-dihydro-1 H-pyrrnlR-?-S-carhnnitrile (37)
LC-MS(ES), m/z: 206 (M+1).
1 -(PipRridine-3-carhnnyl)-?.5-riihyriro-1 H-pyrrnlR-y-S-carhnnitrile (38)
LC-MS(ES), m/z: 206 (M+1).
1 -((3R)-Amino-5-phenyl-pentanoyl)-2.5-dihyrim-1 H-pyrrnlR-(?S)-carhonitrile (39) LC-MS(ES), m/z: 270 (M+1).
1 -((3S)-Aminn-4-phPnyl-hι ityryl )-? 5-dihyriro-1 H-pyrrole-(?S)-carbonitrilR (40)
LC-MS(ES), m/z: 256 (M+1).
1-(MorpholinR-7-r:arhnnyl)-?.5-dihydm-1H-pyrmlR-?-S-r.arhonitrilR(41)
LC-MS(ES), m/z: 208 (M+1). 1 -(3-Aminn-6-phenyl-hex-5-Rnnyl)-?,5-riihyriro-1 H-pyrrole-2-S-carbonitrile (42)
LC-MS(ES), m/z: 281 (M+1). 1-[(3S)-Amino-4-(4-ben7yloxy-phRnyl)-hιιtyryl]-2.5-dihydrn-1 H-pyrrolR-(7S)- carhnnitrile (43)
LC-MS(ES), m/z: 361 (M+1 ).
1 -(7-Pyrroliriin-2-yl-acetyl)-7,5-riihyrlm-1 H-pyrrolfi-2-S-carhnnitrile (44) LC-MS(ES), m/z: 206 (M+1 ).
1-[4-(2-Chlnrn-phRnyl)-pyrroliriine-3-carhonyl]-2.5-dihydro-1 H-pyrrnle-2-S- carhonitrile (45)
LC-MS(ES), m/z: 302 (M+1 ).
1 -(4-Phenyl-pyrrnliriinR-3-carhonyl)-2,5-riihydro-1 H-pyrrnlR-?-S-carhnnitrile (46) LC-MS(ES), m/z: 268 (M+1 ).
Example 2
1 -[7-(R S)-(4-Cyanophenyl)thia7nliriine-4-(R)-carbonyl]-?.5-riihydro-1 H-pyrmle-2- (S)-oarhonitrile (47)
4-Cyanobenzaldehyde (500 mg, 3.8 mmol) was dissolved in 5 ml of ethanol (96%) and L-(+)-cysteine hydrochloride (460 mg, 3.8 mmol) and natriumacetate trihydrate (468 mg, 5.7 mmol) dissolved in 5 ml of water was added. The reaction mixture was stirred for 16 hours at room temperature and the white crystals were collected by filtration and washed twice with 15 ml of wateπethanol (1 :1 ), to afford 400 mg of 2-(RS)-(4- cyanophenyl)thiazolidine-4-(R)-carboxylic acid (48) in 44 % yield. 1 H-NMR (MEOH, 300MHz) δ: 7.69 (m, 4H); 5.81 (s, 1/2H); 5.60 (s, 1/2H); 4.23 (dd, /2H); 4.02 (dd, 1/2H); 3.52- 3.17 (m, 2H).
(265 mg, 1.13 mmol) of (48) was dissolved in 10 ml of tetrahydrofuran, 5 ml of water, and (0.452 ml, 1.13 mmol) of a 10% aqueous solution of sodium hydroxide. Di- tert.-butyl dicarbonate (321 mg, 1.47 mmol) was added and the reaction mixture was stirred for 5 days. Tetrahydrofuran was evaporated off and the remaining was dissolved in 50 ml of ethyl acetate and 50 ml of water, and solid potassium hydrogen sulphate was added until pH=2. The organic material was extracted into 4 x 50 ml of ethyl acetate and the combined organic extracts were washed with 100 ml of water, and 100 ml of brine, and dried over sodium sulphate. The solvent was evaporated to afford 340 mg of 2-(RS)- (4-cyanophenyl)thiazolidine-4-(R)-carboxylic acid 3-carboxylic acid tert-butyl ester (49) as beige crystals in 90% yield. 1 H-NMR (CDCI3, 300MHz) δ: 7.62 (m, 4H); 6.21-5.41 (m, 1 H); 5.02-4.78 (m, 1 H); 3.47-3.21 (m, 2H); 1.42 (s, 3H); 1.24 (s, 6H). LC-MS(ES), m/z: 235.1 (M-99(BOC) and 357.2 (M+23(Na)).
(49) was coupled to (S) 2,5-dihydro-1H-pyrrole-2-carboxylic acid amide and dehydrated with phosphorus oxychloride and finally deprotected with trifluoroacetic acid as described in example 1 , and purified by preparative HPLC to afford 52 mg of the title compound (47). 1 H-NMR (MEOH, 300MHz) δ: 7.75-7.63 (m, 4H); 6.24 (m, 1H); 5.95 (m, 1 H); 5.82 (s, 1/2H); 5.65 (s, 1/2H); 5.48 (m, 1 H); 4.69 (m, 1 H); 4.49 (m, 1 H); 4.27 (m, 1 H); 3.48 (m, 1 H); 3.22 (m, 1 H). LC-MS(ES), m/z: 311.2 (M+1)
The following compounds were prepared by the route outlined in example 2, however, all compounds were also purified by preparative HPLC after the dehydration step.
1-[2-(R.S)-(1-(R.S)-Phenylethyl)thia7niidine-4-(R)-carbonyl]-2,5-dihydrQ-1 H- pyrrnlR-7-(S)-r.arhonitrile (50)
(32 mg) 1 H-NMR (MEOH, 300MHz) δ: ) δ: 7.41-7.15 (m, 5H); 6.80 (dd, 1/2H); 6.45 (dd, 1/2H); 6.20 (m, 1 H); 5.92 (m, 1 H); 5.70 (d, 1/2H); 5.51 (d, 1/2H); 5.45 (m, 1 H); 4.68-4.29 (m, 2H); 4.12-3.88 (m, 1 H); 3.81-2.82 (m, 3H); 1.40 (m, 3H). LC-MS(ES), m/z: 314.2 (M+1 ).
1-(7-(RrS)-PhRnylthia7nliriinR-4-(R)-carhonyl)-2.5-dihyriro-1 H-pyrrnlR-7-(S)- carhonitrile (51 )
(40 mg) 1 H-NMR (MEOH, 300MHz) δ: ) δ: 7.40 (m, 5H); 6.73 (m, 1/2H); 6.48 (m, 1/2H); 6.25 (m, 1 H); 5.98 (m, 1 H); 5.52 (m, 1 H); 5.11 (m, 1 H); 4.72-3.91 (m, 3H); 3.69- 2.91 (m, 2H). LC-MS(ES), m/z: 286.2 (M+1 ).
1 -(Thia7θliriinR-4-(R)-car onyl)-2r5-riihyriro-1 H-pyrrole-2-(S)-carbonitrile (52) (R)-(-)-Thiazolidine-4-carboxylic acid was used as the starting material instead of L- (+)-cysteine hydrochloride as in example 2. The title compound was synthesised as outlined in example 2, starting at the BOC-protection step, to afford 46 mg of (X+7). LC-MS(ES), m/z: 210 (M+1 ).

Claims

1. A compound of formula I
N
Formula I
wherein at least one of the bonds in the five-membered ring is a double bond;
B is any alpha or beta amino acid connected to the ring with an amide or peptide bond; or a salt thereof with a pharmaceutically acceptable acid or base.
2. A compound of formula II
Formula II
wherein at least one of the bonds in the five-membered ring is a double bond; R2 is H; Cι-Cι0 alkyl optionally substituted with one or more R4 independently; C2- Cio alkenyl optionally substituted with one or more R4 independently; C2-Cι0-alkynyl optionally substituted with one or more R4 independently; C3-Cι0-cycloalkyl optionally substituted with one or more R .4 independently; C5-C10 cycloalkenyl optionally substituted with one or more R4 independently; aryl optionally substituted with one or more R5 independently; or heteroaryl optionally substituted with one or more R5 independently;
R3 is H; C1-C10 alkyl optionally substituted with one or more R4 independently; C2- C10 alkenyl optionally substituted with one or more R4 independently; C2-Cιo-alkynyl optionally substituted with one or more R4 independently; C3-C10 cycloalkyl optionally substituted with one or more R4 independently; C5-C10 cycloalkenyl optionally substituted with one or more R4 independently; aryl optionally substituted with one or more R5 independently and/or fused to a C3-C10 cycloalkane; or heteroaryl optionally substituted with one or more R5 independently and/or fused to a C3-C10 cycloalkane;
R2 may be connected to R3 by a saturated or unsaturated bridge containing 1-3 carbon atoms, nitrogen atoms, oxygen atoms, or sulphur atoms independently, or a valence bond, thus forming a ring, said ring may be fused to an aryl or heteroaryl, optionally substituted by one or more R5 independently;
R4 is cycloalkyl, aryl optionally substituted with one or more R5 independently; heteroaryl optionally substituted with one or more R5 independently; amino optionally substituted with one or more R6 independently; -SO-R6; -SO2-R6; -CO-R6; -COO-R6, -
CONH-R6; -CON(R6)2; -O-R6; -S-R6; carboxy; acetamido; cyano; nitro; halogen; hydroxy; trifluoromethyl; trifluoromethoxy; sulfamoyl; carbamoyl; hydroxymethyl;
R5 is halogen, C1-C10 alkyl, C1-C10 alkoxy, C1-C10 alkylamino, C1-C10 dialkylamino, benzyl, benzyloxy, hydroxymethyl, nitro, trifluoromethyl, trifluoromethoxy, trifluoromethylthio, N-hydroxyimino, cyano; carboxy; acetamido; hydroxy; sulfamoyl, carbamoyl;
R6 is C1-C10 alkyl, C2-C10 alkenyl, C2-Cι0-alkynyl, C3-Cιo-cycloalkyl, C5-C10 cycloalkenyl where any one of said alkyl, alkenyl, alkynyl, cycloalkyl, or cykloalkenyl may optionally be substituted with aryl optionally substituted with one or more R5 independently or heteroaryl optionally substituted with one or more R5 independently; benzyl, phenethyl; aryl optionally substituted with one or more R5 independently; or heteroaryl optionally substituted with one or more R5 independently with the proviso that R2 and R3 cannot both be H; or a salt thereof with a pharmaceutically acceptable acid or base.
3. A compound of formula III
Formula
wherein
R2 is H; C1-C10 alkyl optionally substituted with one or more R4 independently; C2- C10 alkenyl optionally substituted with one or more R4 independently; C2-C10-alkynyl optionally substituted with one or more R4 independently; C3-Cι0-cycloalkyl optionally substituted with one or more R4 independently; C5-C10 cycloalkenyl optionally substituted with one or more R4 independently; aryl optionally substituted with one or more R5 independently; or heteroaryl optionally substituted with one or more R5 independently;
R3 is H; C1-C10 alkyl optionally substituted with one or more R4 independently; C2- C10 alkenyl optionally substituted with one or more R4 independently; C2-Cιo-alkynyl optionally substituted with one or more R4 independently; C3-C10 cycloalkyl optionally substituted with one or more R4 independently; C5-C10 cycloalkenyl optionally substituted with one or more R4 independently; aryl optionally substituted with one or more R5 independently and/or fused to a C3-C10 cycloalkane; or heteroaryl optionally substituted with one or more R5 independently and/or fused to a C3-C10 cycloalkane; R2 may be connected to R3 by a saturated or unsaturated bridge containing 1-3 carbon atoms, nitrogen atoms, oxygen atoms, or sulphur atoms independently, or a valence bond, thus forming a ring, said ring may be fused to an aryl or heteroaryl, optionally substituted by one or more R5 independently;
R4 is cycloalkyl, aryl optionally substituted with one or more R5 independently; heteroaryl optionally substituted with one or more R5 independently; amino optionally substituted with one or more R6 independently; -SO-R6; -SO2-R6; -CO-R6; -COO-R6, - CONH-R6; -CON(R6)2; -O-R6; -S-R6; carboxy; acetamido; cyano; nitro; halogen; hydroxy; trifluoromethyl; trifluoromethoxy; sulfamoyl; carbamoyl; hydroxymethyl; R5 is halogen, C1-C10 alkyl, C1-C10 alkoxy, C1-C10 alkylamino, C1-C10 dialkylamino, benzyl, benzyloxy, hydroxymethyl, nitro, trifluoromethyl, trifluoromethoxy, trifluoromethylthio, N-hydroxyimino, cyano; carboxy; acetamido; hydroxy; sulfamoyl, carbamoyl;
R6 is C1-C10 alkyl, C2-Cι0 alkenyl, C2-Cι0-alkynyl, C3-Cι0-cycloalkyl, C5-C10 cycloalkenyl where any one of said alkyl, alkenyl, alkynyl, cycloalkyl, or cykloalkenyl may optionally be substituted with aryl optionally substituted with one or more R5 independently or heteroaryl optionally substituted with one or more R5 independently; benzyl, phenethyl; aryl optionally substituted with one or more R5 independently; or heteroaryl optionally substituted with one or more R independently with the proviso that R2 and R3 cannot both be H; or a salt thereof with a pharmaceutically acceptable acid or base.
4. A compound of formula IV
Formula IV
wherein at least one of the bonds in the five-membered ring is a double bond;
R2 is H; C1-C10 alkyl optionally substituted with one or more R4 independently; C2- C10 alkenyl optionally substituted with one or more R4 independently; C2-Cιo-alkynyl optionally substituted with one or more R4 independently; C3-Cι0-cycloalkyl optionally substituted with one or more R4 independently; C5-C10 cycloalkenyl optionally substituted with one or more R4 independently; aryl optionally substituted with one or more R5 independently; or heteroaryl optionally substituted with one or more R5 independently;
R3 is H; C1-C10 alkyl optionally substituted with one or more R4 independently; C2- C10 alkenyl optionally substituted with one or more R4 independently; C2-Cιo-alkynyl optionally substituted with one or more R4 independently; C3-C10 cycloalkyl optionally substituted with one or more R4 independently; C5-C10 cycloalkenyl optionally substituted with one or more R4 independently; aryl optionally substituted with one or more R5 independently and/or fused to a C3-C10 cycloalkane; or heteroaryl optionally substituted with one or more R5 independently and/or fused to a C3-C10 cycloalkane;
R2 may be connected to R3 or R7 by a saturated or unsaturated bridge containing 1-3 carbon atoms, nitrogen atoms, oxygen atoms, or sulphur atoms independently, or a valence bond, thus forming a ring, said ring may be fused to an aryl or heteroaryl, optionally substituted by one or more R5 independently; R4 is cycloalkyl; aryl optionally substituted with one or more R5 independently; heteroaryl optionally substituted with one or more R5 independently; amino optionally substituted with one or more R6 independently; -SO-R6; -SO2-R6; -CO-R6; -COO-R6, - CONH-R6; -CON(R6)2; -O-R6; -S-R6; carboxy; acetamido; cyano; nitro; halogen; hydroxy; trifluoromethyl; trifluoromethoxy; sulfamoyl; carbamoyl; hydroxymethyl; R5 is halogen, C1-C10 alkyl, C1-C10 alkoxy, C1-C10 alkylamino, C1-C10 dialkylamino, benzyl, benzyloxy, hydroxymethyl, nitro, trifluoromethyl, trifluoromethoxy, trifluoromethylthio, N-hydroxyimino, cyano; carboxy; acetamido; hydroxy; sulfamoyl, carbamoyl;
R6 is C1-C10 alkyl, C2-Cι0 alkenyl, C2-Cιo-alkynyl, C3-Cι0-cycloalkyl, C5-C10 cycloalkenyl where any one of said alkyl, alkenyl, alkynyl, cycloalkyl, or cykloalkenyl may optionally be substituted with aryl optionally substituted with one or more R5 independently or heteroaryl optionally substituted with one or more R5 independently; benzyl, phenethyl; aryl optionally substituted with one or more R5 independently; or heteroaryl optionally substituted with one or more R5 independently; R7 is H; C1-C10 alkyl optionally substituted with one or more R4 independently; C2-
C10 alkenyl optionally substituted with one or more R4 independently; C2-Cι0-alkynyl optionally substituted with one or more R4 independently; C3-Cι0-cycloalkyl optionally substituted with one or more R4 independently; C5-C10 cycloalkenyl optionally substituted with one or more R4 independently; aryl optionally substituted with one or more R5 independently; heteroaryl optionally substituted with one or more R5 independently, halogen, C1-C.0 alkoxy, C1-C10 alkylthio, C1-C10 alkylamino, C1-C10 dialkylamino, hydroxymethyl, nitro, trifluoromethyl, trifluoromethoxy, trifluoromethylthio, N- hydroxyimino, cyano; carboxy; acetamido; hydroxy; sulfamoyl, carbamoyl; with the proviso that the groups R2, R3, and R7 cannot all be H or a salt thereof with a pharmaceutically acceptable acid or base.
5. A compound of formula IV
Formula V
wherein
R2 is H; C1-C10 alkyl optionally substituted with one or more R4 independently; C2-
C10 alkenyl optionally substituted with one or more R4 independently; C2-Cιo-alkynyl optionally substituted with one or more R4 independently; C3-Cι0-cycloalkyl optionally substituted with one or more R4 independently; C5-C10 cycloalkenyl optionally substituted with one or more R4 independently; aryl optionally substituted with one or more R5 independently; or heteroaryl optionally substituted with one or more R5 independently;
R3 is H; C1-C10 alkyl optionally substituted with one or more R4 independently; C2- C10 alkenyl optionally substituted with one or more R4 independently; C2-Cιo-alkynyl optionally substituted with one or more R4 independently; C3-C10 cycloalkyl optionally substituted with one or more R4 independently; C5-C10 cycloalkenyl optionally substituted with one or more R4 independently; aryl optionally substituted with one or more R5 independently and/or fused to a C3-C10 cycloalkane; or heteroaryl optionally substituted with one or more R5 independently and/or fused to a C3-C10 cycloalkane;
R2 may be connected to R3 or R7 by a saturated or unsaturated bridge containing 1-3 carbon atoms, nitrogen atoms, oxygen atoms, or sulphur atoms independently, or a valence bond, thus forming a ring, said ring may be fused to an aryl or heteroaryl, optionally substituted by one or more R5 independently;
R4 is cycloalkyl; aryl optionally substituted with one or more R5 independently; heteroaryl optionally substituted with one or more R5 independently; amino optionally substituted with one or more R6 independently; -SO-R6; -S02-R6; -CO-R6; -COO-R6, - CONH-R6; -CON(R6)2; -O-R6; -S-R6; carboxy; acetamido; cyano; nitro; halogen; hydroxy; trifluoromethyl; trifluoromethoxy; sulfamoyl; carbamoyl; hydroxymethyl;
R5 is halogen, C1-C10 alkyl, C1-C10 alkoxy, C1-C10 alkylamino, C1-C10 dialkylamino, benzyl, benzyloxy, hydroxymethyl, nitro, trifluoromethyl, trifluoromethoxy, trifluoromethylthio, N-hydroxyimino, cyano; carboxy; acetamido; hydroxy; sulfamoyl, carbamoyl;
R6 is C1-C10 alkyl, C2-Cι0 alkenyl, C2-Cιo-alkynyl, C3-Cιo-cycloalkyl, C5-C10 cycloalkenyl where any one of said alkyl, alkenyl, alkynyl, cycloalkyl, or cykloalkenyl may optionally be substituted with aryl optionally substituted with one or more R5 independently or heteroaryl optionally substituted with one or more R5 independently; benzyl, phenethyl; aryl optionally substituted with one or more R5 independently; or heteroaryl optionally substituted with one or more R5 independently;
R7 is H; C1-C10 alkyl optionally substituted with one or more R4 independently; C2- C10 alkenyl optionally substituted with one or more R4 independently; C2-Cι0-alkynyl optionally substituted with one or more R4 independently; C3-Cι0-cycloalkyl optionally substituted with one or more R4 independently; C5-C10 cycloalkenyl optionally substituted with one or more R4 independently; aryl optionally substituted with one or more R5 independently; heteroaryl optionally substituted with one or more R5 independently, halogen, C1-C10 alkoxy, C1-C10 alkylthio, C1-C10 alkylamino, C1-C10 dialkylamino, hydroxymethyl, nitro, trifluoromethyl, trifluoromethoxy, trifluoromethylthio, N- hydroxyimino, cyano; carboxy; acetamido; hydroxy; sulfamoyl, carbamoyl; with the proviso that the groups R2, R3, and R7 cannot all be H or a salt thereof with a pharmaceutically acceptable acid or base.
6. A compound according to any one of claims 2 to 5, wherein
R2 is H; C1-C10 alkyl optionally substituted with R4; C2-Cιo alkenyl optionally substituted with R4; C2-Cι0-alkynyl optionally substituted with R4; aryl optionally substituted with one or more R5 independently; or heteroaryl optionally substituted with one or more R5 independently.
7. A compound according to claim 6, wherein R2 is H or C1-C10 alkyl optionally substituted with R4.
8. A compound according to claim 7, wherein R2 is H.
9. A compound according to any one of the claims 2 to 8, wherein:
R3 is H; C1-C10 alkyl optionally substituted with R4; C2-Cιo alkenyl optionally substituted with R4; C2-Cιo-alkynyl optionally substituted with R4; C3-C10 cycloalkyl optionally substituted with R4; aryl optionally substituted with one or more R5 independently and/or fused to a C3-C10 cycloalkane; or heteroaryl optionally substituted with one or more R5 independently and/or fused to a C3-C10 cycloalkane;
10. A compound according to claim 9, wherein:
R3 is H; C1-C10 alkyl optionally substituted with R4; or aryl optionally substituted with one or more R5 independently and/or fused to a C3-C10 cycloalkane.
11. A compound according to claim 10, wherein R3 is C1-C10 alkyl optionally substituted with R4.
12. A compound according to any one of the claims 2 to 11 , wherein:
R4 is cycloalkyl; aryl optionally substituted with one or more R5 independently; heteroaryl optionally substituted with one or more R5 independently; -SO-R6; -SO2-R6; - CO-R6; -COO-R6; -O-R6; -S-R6;
13. A compound according to claim 12, wherein:
R4 is aryl optionally substituted with one or more R5 independently; heteroaryl optionally substituted with one or more R5 independently; -CO-R6; -COO-R6; -O-R6; -S- R6;
14. A compound according to claim 13, wherein R4 is aryl optionally substituted with one or more R5 independently;
15. A compound according to claim 13, wherein R4 is -COO-R6, -O-R6, or -S-R6;
16. A compound according to any one of the claims 2 to 15, wherein R5 is halogen, C1-C10 alkyl, C1-C10 alkoxy, C1-C10 alkylamino, C1-C10 dialkylamino, benzyl, or benzyloxy.
17. A compound according to claim 16, wherein R5 is halogen, C1-C10 alkyl, or C1-
C10 alkoxy.
18. A compound according to any one of the claims 2 to 17, wherein R6 is C1-C10 alkyl, C2-C10 alkenyl optionally substituted with R4; C2-Cι0-alkynyl optionally substituted with R4; benzyl, aryl optionally substituted with one or more R5 independently, or heteroaryl optionally substituted with one or more R5 independently.
19. A compound according to claim 18, wherein R6 is C1-C10 alkyl, benzyl, or aryl optionally substituted with one or more R5 independently.
20. A pharmaceutical composition comprising, as an active ingredient, at least one compound according to any one of the claims 1 to 19 or a pharmaceutically acceptable salt or prodrug or hydrate thereof together with a pharmaceutically acceptable carrier or diluent.
21. The use of a compound according to any one of the claims 1 to19 for the manufacture of a medicament for use in the treatment of Type II Diabetes.
22. A method of treating Type II Diabetes in humans, which method comprises administering an effective amount of a compound according to any one of the claims 1 to
19.
EP01946849A 2000-01-24 2001-01-22 N-substituted 2-cyanopyroles and -pyrrolines which are inhibitors of the enzyme dpp-iv Withdrawn EP1254113A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200000112 2000-01-24
DK200000112 2000-01-24
DKPA200000983 2000-06-23
DK200000983 2000-06-23
PCT/DK2001/000045 WO2001055105A1 (en) 2000-01-24 2001-01-22 N-substituted 2-cyanopyroles and -pyrrolines which are inhibitors of the enzyme dpp-iv

Publications (1)

Publication Number Publication Date
EP1254113A1 true EP1254113A1 (en) 2002-11-06

Family

ID=26068750

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01946849A Withdrawn EP1254113A1 (en) 2000-01-24 2001-01-22 N-substituted 2-cyanopyroles and -pyrrolines which are inhibitors of the enzyme dpp-iv

Country Status (4)

Country Link
EP (1) EP1254113A1 (en)
JP (1) JP2003520849A (en)
AU (1) AU2001228309A1 (en)
WO (1) WO2001055105A1 (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2116235A1 (en) 2005-01-10 2009-11-11 Arena Pharmaceuticals, Inc. Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level
EP2253311A2 (en) 2006-04-11 2010-11-24 Arena Pharmaceuticals, Inc. Use of GPR119 receptor agonists for increasing bone mass and for treating osteoporosis, as well as combination therapy relating thereto
WO2011005929A1 (en) 2009-07-09 2011-01-13 Arena Pharmaceuticals, Inc. Piperidine derivative and its use for the treatment of diabets and obesity
WO2011127051A1 (en) 2010-04-06 2011-10-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012040279A1 (en) 2010-09-22 2012-03-29 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012135570A1 (en) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145603A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145361A1 (en) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
US10555929B2 (en) 2015-03-09 2020-02-11 Coherus Biosciences, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
US11253508B2 (en) 2017-04-03 2022-02-22 Coherus Biosciences, Inc. PPARy agonist for treatment of progressive supranuclear palsy

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1862457B1 (en) 2001-06-27 2010-01-20 SmithKline Beecham Corporation Fluoropyrrolidines as dipeptidyl peptidase inhibitors
US6861440B2 (en) * 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
WO2003057144A2 (en) * 2001-12-26 2003-07-17 Guilford Pharmaceuticals Change inhibitors of dipeptidyl peptidase iv
PL371678A1 (en) 2002-02-13 2005-06-27 F.Hoffmann-La Roche Ag Novel pyridin- and pyrimidin-derivatives
CN1308311C (en) 2002-02-13 2007-04-04 霍夫曼-拉罗奇有限公司 Novel pyridine- and quinoline-derivatives
HUP0202001A2 (en) * 2002-06-14 2005-08-29 Sanofi-Aventis Azabicyclo-octane and nonane derivatives with ddp-iv inhibiting activity
JP2004026678A (en) * 2002-06-24 2004-01-29 Microbial Chem Res Found Therapeutic agent for type 2 diabetes
TW200401635A (en) 2002-07-23 2004-02-01 Yamanouchi Pharma Co Ltd 2-Cyano-4-fluoropyrrolidine derivative or salt thereof
EP1537880A4 (en) 2002-09-11 2009-07-01 Takeda Pharmaceutical Sustained release preparation
WO2004089362A1 (en) * 2003-04-11 2004-10-21 Novo Nordisk A/S 2-cyanopyrroles and their analogues as ddp-iv inhibitors
AR044019A1 (en) * 2003-04-16 2005-08-24 Novartis Ag PROCESS FOR THE PREPARATION OF N-SUBSTITUTED 2-CYANOPIRROLIDINS
US20040229848A1 (en) * 2003-05-05 2004-11-18 Hans-Ulrich Demuth Glutaminyl based DP IV-inhibitors
ATE462432T1 (en) 2003-05-05 2010-04-15 Probiodrug Ag GLUTAMINYL CYCLASE INHIBITORS
JP5690463B2 (en) 2003-05-05 2015-03-25 プロビオドルグ エージー Use of glutaminyl and glutamate cyclase effectors
EP1961416B1 (en) 2003-05-05 2013-01-23 Probiodrug AG Use of inhibitors of glutaminyl cyclase for treating psoriasis, rheumatoid arthritis or atherosclerosis.
JP4160616B2 (en) 2003-06-20 2008-10-01 エフ．ホフマン−ラ ロシュ アーゲー Pyrido [2,1-a] -isoquinoline derivatives as DPP-IV inhibitors
CA2528784C (en) 2003-06-20 2012-02-21 Markus Boehringer Hexahydropyridoisoquinolines as dpp-iv inhibitors
CA2542419C (en) 2003-10-15 2013-06-04 Probiodrug Ag Use of glutamyl cyclase inhibitors in the treatment of familial british dementia and familial danish dementia
NZ546887A (en) 2003-11-03 2009-04-30 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
KR20180050427A (en) 2003-11-17 2018-05-14 노파르티스 아게 Use of dipeptidyl peptidase iv inhibitors
RS62595B1 (en) 2004-01-20 2021-12-31 Novartis Ag Direct compression formulation and process
WO2005073186A1 (en) * 2004-01-29 2005-08-11 Ono Pharmaceutical Co., Ltd. Pyrrolidine derivatives
BRPI0507485A (en) 2004-02-05 2007-07-10 Probiodrug Ag new glutaminyl cyclase inhibitors
ES2375625T3 (en) * 2004-02-05 2012-03-02 Kyorin Pharmaceutical Co., Ltd. ESTER BICYCLE DERIVATIVES.
WO2005077900A1 (en) * 2004-02-18 2005-08-25 Kyorin Pharmaceutical Co., Ltd. Bicyclic amide derivatives
CA2557275C (en) * 2004-02-27 2012-06-05 Kyorin Pharmaceutical Co., Ltd. Bicyclo derivative
JP2007538079A (en) * 2004-05-18 2007-12-27 メルク　エンド　カムパニー　インコーポレーテッド Cyclohexylalanine derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
US20060024370A1 (en) * 2004-07-29 2006-02-02 Cephalon France Modafinil oral lyophilizate
BRPI0516340A (en) * 2004-10-12 2008-09-16 Glenmark Pharmaceuticals Sa compound, pharmaceutical composition, method for treating a condition that is regulated or normalized via dpp-iv inhibition, method for treating a metabolic disorder, method for treating type ii diabetes, method for lowering blood glucose, method for treating and prophylaxis of a disease, method for treating undamaged insulin-resistant glucose tolerance, method for the manufacture of a pharmaceutical composition and process for the preparation of compounds
US7411093B2 (en) 2004-12-20 2008-08-12 Hoffman-La Roche Inc. Aminocycloalkanes as DPP-IV inhibitors
RU2396257C2 (en) 2004-12-20 2010-08-10 Ф.Хоффманн-Ля Рош Аг 4-aminopyperidine derivatives
EP2602259A3 (en) 2005-02-18 2014-09-10 Mitsubishi Tanabe Pharma Corporation Salt of proline derivative, solvate thereof, and production method thereof
MY152185A (en) 2005-06-10 2014-08-29 Novartis Ag Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
WO2006134613A2 (en) * 2005-06-17 2006-12-21 Aurigene Discovery Technologies Limited Novel 5-substituted indole derivatives as dipeptidyl peptidase iv (dpp-iv) inhibitors
EP1760076A1 (en) 2005-09-02 2007-03-07 Ferring B.V. FAP Inhibitors
ATE532518T1 (en) 2005-09-14 2011-11-15 Takeda Pharmaceutical DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OF DIABETES
KR101368988B1 (en) 2005-09-16 2014-02-28 다케다 야쿠힌 고교 가부시키가이샤 Dipeptidyl peptidase inhibitors
GB0526291D0 (en) 2005-12-23 2006-02-01 Prosidion Ltd Therapeutic method
US20090156465A1 (en) 2005-12-30 2009-06-18 Sattigeri Jitendra A Derivatives of beta-amino acid as dipeptidyl peptidase-iv inhibitors
US7915427B2 (en) 2006-03-08 2011-03-29 Kyorin Pharmaceuticals Co., Ltd. Process for producing aminoacetyl pyrrolidine carbonitrile derivative and intermediate for production thereof
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
KR20090004950A (en) 2006-04-12 2009-01-12 프로비오드룩 아게 Enzyme inhibitors
EP2089383B1 (en) 2006-11-09 2015-09-16 Probiodrug AG 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
WO2008114857A1 (en) 2007-03-22 2008-09-25 Kyorin Pharmaceutical Co., Ltd. Method for producing aminoacetylpyrrolidinecarbonitrile derivative
US9656991B2 (en) 2007-04-18 2017-05-23 Probiodrug Ag Inhibitors of glutaminyl cyclase
EP2108960A1 (en) 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
JP5476305B2 (en) 2008-08-07 2014-04-23 杏林製薬株式会社 Method for producing bicyclo [2.2.2] octylamine derivative
JP5934645B2 (en) 2009-09-11 2016-06-15 プロビオドルグ エージー Heterocyclic derivatives as glutaminyl cyclase inhibitors
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
SG183229A1 (en) 2010-03-10 2012-09-27 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
WO2018162722A1 (en) 2017-03-09 2018-09-13 Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke Dpp-4 inhibitors for use in treating bone fractures
EP3461819B1 (en) 2017-09-29 2020-05-27 Probiodrug AG Inhibitors of glutaminyl cyclase
CN115322129A (en) * 2022-08-29 2022-11-11 湖北科技学院 Dicyano pyrrolidine derivative and preparation method and application thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122010000020I1 (en) * 1996-04-25 2010-07-08 Prosidion Ltd Method for lowering the blood glucose level in mammals
US6011155A (en) * 1996-11-07 2000-01-04 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
TW492957B (en) * 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
EP2433623A1 (en) * 1998-02-02 2012-03-28 Trustees Of Tufts College Use of dipeptidylpeptidase inhibitors to regulate glucose metabolism
DE19834591A1 (en) * 1998-07-31 2000-02-03 Probiodrug Ges Fuer Arzneim Use of substances that decrease the activity of dipeptidyl peptidase IV to increase blood sugar levels, e.g. for treating hypoglycemia
CO5150173A1 (en) * 1998-12-10 2002-04-29 Novartis Ag COMPOUNDS N- (REPLACED GLYCLE) -2-DIPEPTIDYL-IV PEPTIDASE INHIBITING CYANOPIRROLIDINS (DPP-IV) WHICH ARE EFFECTIVE IN THE TREATMENT OF CONDITIONS MEDIATED BY DPP-IV INHIBITION
US6110949A (en) * 1999-06-24 2000-08-29 Novartis Ag N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0155105A1 *

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7803753B2 (en) 2005-01-10 2010-09-28 Arena Pharmaceuticals, Inc. Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level
US7803754B2 (en) 2005-01-10 2010-09-28 Arena Pharmaceuticals, Inc. Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level
EP2116235A1 (en) 2005-01-10 2009-11-11 Arena Pharmaceuticals, Inc. Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level
EP2253311A2 (en) 2006-04-11 2010-11-24 Arena Pharmaceuticals, Inc. Use of GPR119 receptor agonists for increasing bone mass and for treating osteoporosis, as well as combination therapy relating thereto
WO2011005929A1 (en) 2009-07-09 2011-01-13 Arena Pharmaceuticals, Inc. Piperidine derivative and its use for the treatment of diabets and obesity
WO2011127051A1 (en) 2010-04-06 2011-10-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012040279A1 (en) 2010-09-22 2012-03-29 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
EP3323818A1 (en) 2010-09-22 2018-05-23 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012135570A1 (en) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145361A1 (en) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145603A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
US10555929B2 (en) 2015-03-09 2020-02-11 Coherus Biosciences, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
US10772865B2 (en) 2015-03-09 2020-09-15 Coherus Biosciences, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
US11400072B2 (en) 2015-03-09 2022-08-02 Coherus Biosciences, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
US11253508B2 (en) 2017-04-03 2022-02-22 Coherus Biosciences, Inc. PPARy agonist for treatment of progressive supranuclear palsy

Also Published As

Publication number Publication date
WO2001055105A1 (en) 2001-08-02
AU2001228309A1 (en) 2001-08-07
JP2003520849A (en) 2003-07-08

Similar Documents

Publication Publication Date Title
US6380398B2 (en) Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV
WO2001055105A1 (en) N-substituted 2-cyanopyroles and -pyrrolines which are inhibitors of the enzyme dpp-iv
KR101292707B1 (en) Inhibitors of dipeptidylpeptidase iv
EP1385508B1 (en) Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US20030199528A1 (en) Hetrocyclic compounds that are inhibitors of the enzyme DPP-IV
RU2309161C2 (en) Effectors of dipeptidyl peptidase iv
US7192952B2 (en) Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
EP1301187B1 (en) Purine-2,6-diones which are inhibitors of the enzyme dipeptidyl peptidase iv (dpp-iv)
JP4800964B2 (en) Heteroarylindolecarboxamides and analogs thereof for use as glucokinase activators in the treatment of obesity
US7727964B2 (en) Peptidomimetic inhibitors of post-proline cleaving enzymes
JP3681110B2 (en) N-substituted 2-cyanopyrrolidine
US7825139B2 (en) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
JP2005513165A (en) Methods and compositions for the treatment of diabetes, hypertension, chronic heart failure and fluid retention
EP3172199B1 (en) Pyrimidine derivatives as glp-1 receptor modulators
US20090325889A1 (en) Hepatitis c serine protease inhibitors and uses therefor
JP2018044005A (en) Methods of regulating glucose metabolism, and reagents related thereto
AU2017228398A1 (en) Small molecule IRE1-alpha inhibitors
AU2002306823A1 (en) Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
JP2005500308A (en) Dipeptidyl peptidase inhibitors for the treatment of diabetes
JP2006527704A5 (en)
WO2006059163A1 (en) Treatment of diabetes with glycogen phosphorylase inhibitors
US8748457B2 (en) 2-amino-2- [8-(dimethyl carbamoyl)- 8-aza- bicyclo [3.2.1] oct-3-yl]-exo- ethanoyl derivatives as potent DPP-IV inhibitors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020826

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17Q First examination report despatched

Effective date: 20040311

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040721